{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.16243"}, {"@name": "filename", "#text": "22822_000909787.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL \n\nCENTRO DE BIOTECNOLOGIA \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM BIOLOGIA CELULAR E MOLECULAR \n\n \n\n \n\n \n\nAVALIA\u00c7\u00c3O DE PAR\u00c2METROS COMPORTAMENTAIS E BIOMARCADORES \n\nDE ESTRESSE OXIDATIVO EM CAMUNDONGOS Idua\n-/-\n\n, UM MODELO \n\nGEN\u00c9TICO DE MUCOPOLISSACARIDOSE DO TIPO I \n\n \n\nGUSTAVO KELLERMANN REOLON \n\n \n\nDisserta\u00e7\u00e3o submetida ao \n\nPrograma de P\u00f3s-Gradua\u00e7\u00e3o em \n\nBiologia Celular e Molecular da \n\nUFRGS como requisito parcial \n\npara a obten\u00e7\u00e3o do grau de \n\nMestre em Ci\u00eancias. \n\n \n\nOrientador: Prof. Dr. Rafael Roesler \n\n \n\nPORTO ALEGRE \n\nFEVEREIRO DE 2007 \n\n\n\n \n\nINSTITUI\u00c7\u00d5ES \n\n \n\n Este trabalho foi desenvolvido no Laborat\u00f3rio de Neurofarmacologia Celular \n\ne Molecular (Departamento de Farmacologia, Instituto de Ci\u00eancias B\u00e1sicas da \n\nSa\u00fade/Centro de Biotecnologia/UFRGS), no Laborat\u00f3rio de Imunogen\u00e9tica \n\n(Departamento de Gen\u00e9tica, Instituto de Ci\u00eancias B\u00e1sicas da Sa\u00fade/UFRGS), no \n\nLaborat\u00f3rio de Fisiopatologia Experimental (Departamento de \n\nMedicina/Universidade do Extremo Sul Catarinense) e no Centro de Estudos em \n\nEstresse Oxidativo (Departamento de Bioqu\u00edmica, Instituto de Ci\u00eancias B\u00e1sicas \n\nda Sa\u00fade/ UFRGS). \n\n \n\n \n\nFONTES FINANCIADORAS \n\n \n\n Este estudo foi financiado pelo Instituto Mil\u00eanio-Rede de Terapia G\u00eanica \n\n(CNPq/Edital Institutos do Mil\u00eanio-01/2005) e pelas ag\u00eancias: CAPES, CNPq, \n\nPROPESQ e FAPERGS. \n\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDedico este trabalho \u00e0 minha fam\u00edlia, \n\nque sempre esteve presente quando \n\nprecisei, me auxiliando nas dificuldades \n\ne partilhando das alegrias nas \n\nconquistas. \n\nAo meu pai, minha m\u00e3e e minha irm\u00e3: \n\nsem os quais, nada disso teria sido \n\nposs\u00edvel. \n\n\n\n \n\nAGRADECIMENTOS \n\n \n\n Ao meu orientador, Dr. Rafael Roesler, pelos valiosos ensinamentos que \n\nvou aproveitar durante toda minha carreira acad\u00eamica. Por sempre acreditar na \n\nminha capacidade, me incentivando e permitindo que eu desenvolvesse este \n\ntrabalho. Pelas palavras de conforto sempre convincentes quando necess\u00e1rias.  \n\n \u00c0 Professora Dra. Nance Nardi, pela oportunidade, acreditando e confiando \n\nna realiza\u00e7\u00e3o desse trabalho. Pelo grande exemplo cient\u00edfico e pessoal. \n\n \u00c0 Luisa Macedo Braga, pessoa incr\u00edvel, que possibilitou a realiza\u00e7\u00e3o desse \n\ntrabalho, pelo seu aux\u00edlio e amizade.  \n\n \u00c0 Melissa Camassola, pelo aux\u00edlio na realiza\u00e7\u00e3o deste trabalho, pelas \n\nconversas sobre as possibilidades de continua\u00e7\u00e3o do mesmo, sempre que uma \n\nideia surgia. Pela amizade e companheirismo. \n\n \u00c0 Tatiana Luft, pelos ensinamentos e aux\u00edlio na realiza\u00e7\u00e3o dos \n\nexperimentos. \n\n \u00c0 Adalisa Reinke e Marcos Roberto de Oliveira,\n \npelo enorme aux\u00edlio na \n\nrealiza\u00e7\u00e3o dos experimentos de biomarcadores de estresse oxidativo. \n\n Ao Professor Felipe Dal\u00b4Pizzol, pelo aux\u00edlio neste trabalho. \n\n Ao Professor Guido, pelos ensinamentos e sugest\u00f5es importantes.  \n\n \u00c0 banca, pela disponibilidade e paci\u00eancia.\n\n Aos colegas Marianne, D\u00e9bora, Caroline, Bruno, Thales, Natasha, Andr\u00e9ia, \n\nDaniela Corn\u00e9lio, Daniela Lessa, Rodrigo e Luciana que fizeram do nosso \n\nlaborat\u00f3rio um lugar agrad\u00e1vel e prazeroso de trabalhar.  \n\n Aos demais amigos do Laborat\u00f3rio de Pesquisas em C\u00e2ncer. \n\n Aos amigos do Laborat\u00f3rio de Imunogen\u00e9tica, em especial \u00e0 Fl\u00e1via.  \n\n Aos amigos do Laborat\u00f3rio 210 e 212 da Biof\u00edsica, sem os quais o Campus \n\ndo Vale n\u00e3o seria o mesmo. \n\n\n\n \n\n \u00c0 Silvia e ao Luciano, por toda ajuda e boa vontade, tornando a secretaria \n\num local agrad\u00e1vel.  \n\n \u00c0 minha fam\u00edlia, pelo aux\u00edlio em momentos cruciais e pela compreens\u00e3o \n\nnecess\u00e1ria para com um mestrando. Embora n\u00e3o compreendessem todo o meu \n\ntrabalho, o apoiaram plenamente. Ao meu pai, pelos conselhos valiosos e aux\u00edlio \n\nna rotina. \u00c0 minha m\u00e3e, pelas discuss\u00f5es filos\u00f3ficas e cient\u00edficas, pela ajuda na \n\ncorre\u00e7\u00e3o ortogr\u00e1fica e gramatical da disserta\u00e7\u00e3o. \u00c0 minha irm\u00e3, pelo aux\u00edlio \n\nincondicional e ajuda na organiza\u00e7\u00e3o das refer\u00eancias bibliogr\u00e1ficas desta \n\ndisserta\u00e7\u00e3o. \n\n A todos que contribu\u00edram de alguma forma para este trabalho e n\u00e3o foram \n\naqui citados, meus sinceros agradecimentos. \n\n A todos os pesquisadores que contribu\u00edram para os conhecimentos \n\nutilizados nesta disserta\u00e7\u00e3o. \n\n \n\n\n\n \n\n\u00cdNDICE \n\n \n\nLISTA DE ABREVIATURAS ........................................................................ 7 \n\nRESUMO ...................................................................................................... 8 \n\nABSTRACT .................................................................................................. 9 \n\nINTRODU\u00c7\u00c3O ........................................................................................... 10 \n\nOBJETIVOS ............................................................................................... 18 \n\nARTIGO 1 ................................................................................................... 19 \n\nARTIGO 2 ................................................................................................... 26 \n\nDISCUSS\u00c3O .............................................................................................. 33 \n\nREFER\u00caNCIAS BIBLIOGR\u00c1FICAS .......................................................... 43 \n\nCURRICULUM VITAE RESUMIDO ............................................................ 49 \n\n \n\n \n\n\n\n \n\n7 \n\n \n\nLISTA DE ABREVIATURAS \n\n \n\nEROs: Esp\u00e9cies reativas de oxig\u00eanio \n\nERNs: Esp\u00e9cies reativas de nitrog\u00eanio \n\nGAGs: glicosaminoglicanos \n\nGM2: ganglios\u00eddeo GM2  \n\nGM3: ganglios\u00eddeo GM3 \n\nGPx: glutationa peroxidase \n\nIDUA: enzima ?-L-iduronidase \n\nLSD: doen\u00e7as de ac\u00famulo lisossomal \n\nMDA: dialde\u00eddo mal\u00f4nico \n\nMLD: leucodistrofia metacrom\u00e1tica \n\nMPS: mucopolissacaridoses \n\nnNOS: \u00f3xido n\u00edtrico sintetasa \n\nNPC: Niemann-Pick do tipo C \n\nSNC: sistema nervoso central \n\nSOD: super\u00f3xido dismutase \n\nTBARS: esp\u00e9cies reativas ao \u00e1cido tiobarbit\u00farico \n\n\n\n \n\n8 \n\n \n\nRESUMO \n\n \n\n Mucopolissacaridose do tipo I (MPS I) \u00e9 uma doen\u00e7a de ac\u00famulo \n\nlisossomal que leva a neurodegenera\u00e7\u00e3o e d\u00e9ficits neurol\u00f3gicos, entre outras \n\nconseq\u00fc\u00eancias patol\u00f3gicas e cl\u00ednicas. A aus\u00eancia de estudos sobre par\u00e2metros \n\nneurocomportamentais do modelo murino de MPS I capazes de avaliar sua \n\nfun\u00e7\u00e3o cognitiva motivou a realiza\u00e7\u00e3o deste trabalho. O primeiro nosso objetivo \n\nfoi analisar par\u00e2metros cognitivos que possam ser utilizados na avalia\u00e7\u00e3o de \n\ndiferentes terapias e seus efeitos sobre o SNC. Durante a explora\u00e7\u00e3o do \n\ncampo aberto, camundongos MPS I (Idua\n-/-\n\n) adultos mostraram locomo\u00e7\u00e3o e \n\nansiedade normais, mas reduzido n\u00famero de rearings. Camundongos Idua\n-/-\n\n \n\ntiveram uma performance normal no reconhecimento de objeto novo e \n\nmostraram mem\u00f3ria de curta dura\u00e7\u00e3o de esquiva inibit\u00f3ria normal. Entretanto a \n\nmem\u00f3ria de longa dura\u00e7\u00e3o de esquiva inibit\u00f3ria estava prejudicada. O d\u00e9ficit \n\nobservado na esquiva inibit\u00f3ria n\u00e3o pode ser atribu\u00eddo a redu\u00e7\u00e3o na reatividade \n\nao choque. Os resultados indicam que camundongos Idua\n-/-\n\n apresentam um \n\nd\u00e9ficit na mem\u00f3ria de longa dura\u00e7\u00e3o para treinamento aversivo e \n\ncomportamento explorat\u00f3rio. O segundo objetivo foi avaliar biomarcadores de \n\nestresse oxidativo neste modelo animal. N\u00f3s avaliamos atividade enzim\u00e1tica \n\nantioxidante, dano a prote\u00ednas e peroxida\u00e7\u00e3o lip\u00eddica no telenc\u00e9falo, cerebelo, \n\ncora\u00e7\u00e3o, pulm\u00e3o, diafragma, f\u00edgado, rim, e ba\u00e7o. De oito \u00f3rg\u00e3os analisados, \n\nsete tiveram altera\u00e7\u00e3o em no m\u00ednimo um par\u00e2metro. Os resultados indicam que \n\ncamundongos Idua\n-/-\n\n podem estar sofrendo estresse oxidativo. \n\n\n\n \n\n9 \n\n \n\nABSTRACT \n\n \n\n Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease \n\nthat leads to neurodegeneration and neurological deficits, among other \n\npathological and clinical consequences. The absence of behavioral parameters \n\nfrom the MPS I mouse model motivated the accomplishment of this work.  Our \n\nfirst objective was to analyze behavioral parameters that might be used to \n\nessay the effect of different therapies on the CNS. During exploration of an \n\nopen field, adult MPS I (Idua\n-/-\n\n) mice showed normal locomotion and anxiety, \n\nbut reduced number of rearings. Idua\n-/-\n\n mice performed normally in a novel \n\nobject recognition memory task and showed normal short-term retention of \n\ninhibitory avoidance training. By contrast, long-term retention of inhibitory \n\navoidance was impaired. The deficit in inhibitory avoidance memory could not \n\nbe attributed to reduced footshock reactivity. The results indicate that Idua\n-/-\n\n \n\nmice present deficits in long-term memory for aversive training and reduced \n\nexploratory behavior. The second aim was to evaluate oxidative biomarkers on \n\nthis mice model. We evaluated antioxidant enzymatic activity, protein damage \n\nand lipid peroxidation on forebrain, cerebellum, heart, lung, diaphragm, liver, \n\nkidney and spleen. From eight analyzed organs, seven had alteration on at \n\nleast one parameter. The results indicate that Idua\n-/-\n\n mice can be under \n\noxidative stress. \n\n \n\n\n\n \n\n10 \n\n \n\nINTRODU\u00c7\u00c3O \n\n \n\n As Doen\u00e7as de Ac\u00famulo Lisossomal (LSD) s\u00e3o causadas por defeitos na \n\natividade de prote\u00ednas lisossomais, resultando no ac\u00famulo de metab\u00f3litos n\u00e3o \n\ndegradados dentro do lisossomo. Esse ac\u00famulo causa altera\u00e7\u00f5es nas c\u00e9lulas, \n\nnos tecidos e nos \u00f3rg\u00e3os (NEUFELD &amp; MUENZER, 2001). \n\n Os lisossomos cont\u00eam cerca de 50 a 60 hidrolases (JOURNET et al., \n\n2002) e, no m\u00ednimo, sete prote\u00ednas transmembranas (ESKELINEN et al., 2003). \n\nTeoricamente, muta\u00e7\u00f5es em qualquer gene codificante dessas prote\u00ednas \n\npodem causar LSD. At\u00e9 o momento, s\u00e3o conhecidas mais de 40 LSD \n\nenvolvendo defeitos em hidrolases. \n\n As LSD s\u00e3o normalmente monog\u00eanicas e podem existir no fen\u00f3tipo \n\nclassificado como infantil, juvenil ou adulto. O fen\u00f3tipo mais grave, o infantil, \n\napresenta dano ao Sistema Nervoso Central (SNC) nos primeiros anos de vida \n\ne morte na primeira d\u00e9cada. O fen\u00f3tipo adulto tem seus sinais mais brandos, \n\nhavendo pouco ou nenhum dano ao SNC e as les\u00f5es perif\u00e9ricas s\u00e3o as \n\nprincipais modifica\u00e7\u00f5es - aumento do f\u00edgado e ba\u00e7o (hepatoesplenomegalia), \n\nanormalidades esquel\u00e9ticas e danos ao cora\u00e7\u00e3o e ao rim. O fen\u00f3tipo juvenil \n\napresenta altera\u00e7\u00f5es intermedi\u00e1rias entre o infantil e o adulto (FUTERMAN &amp; \n\nVAN MEER, 2004). \n\n Uma quest\u00e3o importante a ser respondida sobre as LSD \u00e9 quanto \u00e0s rotas \n\nbioqu\u00edmicas e celulares que causam a fisiopatologia da doen\u00e7a. O ac\u00famulo de \n\nmetab\u00f3litos leva a disfun\u00e7\u00f5es na c\u00e9lula: o compartimento lisossomal cresce em \n\n\n\n \n\n11 \n\n \n\ntamanho e n\u00famero na tentativa de armazenar o aumento progressivo da \n\nconcentra\u00e7\u00e3o dos metab\u00f3litos. Contudo, a interpreta\u00e7\u00e3o dessa disfun\u00e7\u00e3o \n\ncelular n\u00e3o explicaria toda a complexidade da doen\u00e7a (JEYAKUMAR et al., \n\n2005). O ac\u00famulo de substratos no lisossomo \u00e9 a causa prim\u00e1ria do dano, \n\nentretanto, devido \u00e0 extensa sintomatologia observada, sup\u00f5e-se que haja \n\nrotas de danos secund\u00e1rios e/ou terci\u00e1rios (FUTERMAN &amp; VAN MEER, 2004). \n\n As LSD s\u00e3o classificadas de acordo com o substrato acumulado. As \n\nmucopolissacaridoses (MPS) acumulam glicosaminoglicanos (GAGs), \n\nantigamente denominados mucopolissacar\u00eddeos. Os glicosaminoglicanos s\u00e3o \n\npolissacar\u00eddeos lineares de cadeia longa. Existem quatro tipos de GAGs: \n\ndermatan sulfato, heparan sulfato, keratan sulfato e condroitin sulfato; sendo \n\nque todos podem ser acumulados nas MPS. Esses polissacar\u00eddeos integram \n\nmacromol\u00e9culas da matriz extracelular, dos fluidos articulares e do tecido \n\nconjuntivo do corpo humano, podendo tamb\u00e9m constituir a superf\u00edcie celular \n\n(BERNFIELD et al., 1999; IOZZO, 2001). Entre as fun\u00e7\u00f5es normais dessas \n\nmol\u00e9culas, est\u00e3o a sinaliza\u00e7\u00e3o na jun\u00e7\u00e3o neuromuscular (WALLACE, 1989; \n\nHOCH, 1999), a forma\u00e7\u00e3o da cartilagem e da jun\u00e7\u00e3o neuromuscular \n\n(ARIKAWA-HIRASAWA et al., 2001; ARIKAWA-HIRASAWA &amp; YAMADA, \n\n2001), a manuten\u00e7\u00e3o da retina (SERTIE et al., 2000) e da integridade do \n\nglom\u00e9rulo (GROFFEN et al., 1999). \n\n Existem seis diferentes MPS classificadas numericamente como I, II, III, \n\nIV, VI e VII. S\u00e3o causadas pelo d\u00e9ficit de onze enzimas necess\u00e1rias para a \n\ndegrada\u00e7\u00e3o sequencial dos GAGs. Essas enzimas incluem exoglicosidades, \n\nsulfatases e uma transferase (FUTERMAN &amp; VAN MEER, 2004). \n\n\n\n \n\n12 \n\n \n\nO fen\u00f3tipo dos pacientes afetados e o tipo de GAG acumulado variam \n\ndependendo da enzima afetada e de sua atividade residual. Em geral, todos os \n\nportadores da doen\u00e7a apresentam um quadro progressivo com envolvimento \n\nde m\u00faltiplos \u00f3rg\u00e3os e altera\u00e7\u00f5es faciais. As MPS s\u00e3o doen\u00e7as autoss\u00f4micas \n\nrecessivas, com exce\u00e7\u00e3o da MPS II, que \u00e9 ligada ao cromossomo X. \n\n A MPS I \u00e9 causada pela defici\u00eancia da enzima ?-L-iduronidase, \n\nnecess\u00e1ria para a quebra de dermatan sulfato e heparan sulfato. Essa enzima \n\n\u00e9 uma exoglicosidade, hidrolisando res\u00edduos de \u00e1cido ?-L-idur\u00f4nico na por\u00e7\u00e3o \n\nterminal de heparan e keratan sulfato. Esse \u00e9 o primeiro passo na rota normal \n\nde degrada\u00e7\u00e3o dos GAGs mencionados acima. \n\n O heparan sulfato est\u00e1 presente no c\u00e9rebro, no tecido conjuntivo, no \n\nc\u00f3rtex \u00f3sseo, na placa de crescimento \u00f3sseo, no cora\u00e7\u00e3o, nos cabelos, no \n\nf\u00edgado e no rim. O dermatan sulfato \u00e9 encontrado no c\u00f3rtex e na placa de \n\ncrescimento \u00f3sseo. Esses dois polissacar\u00eddeos est\u00e3o presentes em \n\npraticamente todos os tecidos do corpo humano. Dessa forma, a MPS I \n\napresenta um n\u00famero grande de tecidos afetados. \n\n A defici\u00eancia de ?-L-iduronidase pode resultar num espectro amplo da \n\ndoen\u00e7a, havendo tr\u00eas subtipos: Hurler, o fen\u00f3tipo infantil; Scheie, o fen\u00f3tipo \n\nadulto, e um intermedi\u00e1rio, Hurler-Scheie. Outros fen\u00f3tipos que n\u00e3o se \n\nenquadram nos tr\u00eas subtipos podem ocorrer. O diagn\u00f3stico da MPS I \u00e9 \n\nconfirmado por um n\u00edvel baixo ou indetect\u00e1vel da enzima nos leuc\u00f3citos ou nos \n\nfibroblastos da pele e por uma concentra\u00e7\u00e3o alta de fragmentos de GAGs na \n\nurina. \n\n\n\n \n\n13 \n\n \n\n Os pacientes com s\u00edndrome de Hurler s\u00e3o normais ao nascimento, \n\ndesenvolvendo os sintomas da patologia mais tarde. O diagn\u00f3stico da doen\u00e7a \n\n\u00e9 geralmente feito entre seis e 24 meses e as anormalidades incluem atraso no \n\ncrescimento, problemas card\u00edacos, altera\u00e7\u00f5es faciais e esquel\u00e9ticas, perda de \n\nvis\u00e3o e audi\u00e7\u00e3o, aumento de excre\u00e7\u00e3o de GAGs na urina, problemas \n\narticulares, organomegalias e comprometimento do SNC com retardo mental \n\ngrave (NEUFELD &amp; MUENZER, 2001). A morte dos pacientes ocorre entre oito \n\ne 10 anos devido a problemas card\u00edacos e/ou respirat\u00f3rios. \n\n A forma mais branda da MPS I, a s\u00edndrome de Scheie, apresenta \n\nopacifica\u00e7\u00e3o da c\u00f3rnea, problemas articulares e valvulopatias. A intelig\u00eancia e \n\nestatura s\u00e3o normais. O diagn\u00f3stico da doen\u00e7a \u00e9 geralmente feito entre 10 e 20 \n\nanos de idade, sendo normal a expectativa de vida. \n\n A s\u00edndrome de Hurler-Scheie apresenta um fen\u00f3tipo intermedi\u00e1rio com \n\nenvolvimento de m\u00faltiplos \u00f3rg\u00e3os, disostose m\u00faltipla e pouca ou nenhuma \n\ndisfun\u00e7\u00e3o intelectual. O diagn\u00f3stico \u00e9 normalmente feito entre tr\u00eas e oito anos. \n\nGeralmente, os pacientes sobrevivem at\u00e9 a idade adulta. \n\n A ?-L-iduronidase, assim como outras hidrolases afetadas nas LSD, \u00e9 \n\ndirecionada do complexo de Golgi para o lisossomo atrav\u00e9s da marca\u00e7\u00e3o com \n\nres\u00edduos de manose-6-fosfato. Esses res\u00edduos s\u00e3o reconhecidos por \n\nreceptores de manose-6-fosfato e internalizados no lisossomo (MYEROWITZ &amp; \n\nNEUFELD, 1981). Como esses receptores tamb\u00e9m se encontram na \n\nmembrana plasm\u00e1tica, hidrolases marcadas podem \u201cescapar\u201d de c\u00e9lulas \n\nprodutoras dessas enzimas e serem internalizadas por c\u00e9lulas que n\u00e3o \n\napresentam hidrolases funcionais, permitindo que c\u00e9lulas deficientes recebam \n\n\n\n \n\n14 \n\n \n\nas enzimas e diminuam o ac\u00famulo lisossomal. Esse \u00e9 o princ\u00edpio utilizado nas \n\nterapias de reposi\u00e7\u00e3o enzim\u00e1tica e g\u00eanica para tratamento das LSD. \n\n As terap\u00eauticas aprovadas para MPS I s\u00e3o a terapia de reposi\u00e7\u00e3o \n\nenzim\u00e1tica e o transplante de medula \u00f3ssea. Na terapia de reposi\u00e7\u00e3o \n\nenzim\u00e1tica, existe a possibilidade de utilizar enzimas modificadas com melhor \n\ncapta\u00e7\u00e3o pelas c\u00e9lulas, maior atividade e/ou melhor estabilidade para \n\nmaximizar sua efic\u00e1cia. A principal vantagem do transplante de medula \u00f3ssea \u00e9 \n\na produ\u00e7\u00e3o da enzima pelas c\u00e9lulas do Sistema Imunol\u00f3gico transplantado. \n\n Nas LSD, a corre\u00e7\u00e3o do dano ao SNC \u00e9 o maior desafio e continua sem \n\nsolu\u00e7\u00e3o. N\u00e3o existe tratamento eficaz para a les\u00e3o cerebral em pacientes \n\nportadores de LSD (JEYAKUMAR et al., 2005); e, infelizmente, a maioria \n\ndessas doen\u00e7as afeta o SNC (WRAITH, 2004). As hidrolases n\u00e3o atravessam a \n\nbarreira hematoencef\u00e1lica. Dessa forma, as terapias de reposi\u00e7\u00e3o enzim\u00e1tica e \n\ng\u00eanica n\u00e3o atingem o SNC, exceto em caso de administra\u00e7\u00e3o direta. No \n\ntransplante de medula \u00f3ssea, a enzima chega ao SNC atrav\u00e9s de macr\u00f3fagos \n\nque cruzam a barreira hematoencef\u00e1lica (NEUMANN, 2006). Entretanto, \n\nproblemas como a incompatibilidade doador-receptor dificultam o uso rotineiro \n\ndessa terapia. \n\n Na MPS I, \u00e9 desconhecida a etiologia da neurodegenera\u00e7\u00e3o. Nos \n\nmodelos de MPS I, foram observadas altera\u00e7\u00f5es morfol\u00f3gicas neuronais \n\n(DEKABAN &amp; CONSTANTOPOULOS, 1977; WALKLEY et al., 1988). Contudo, \n\nsua influ\u00eancia na patologia n\u00e3o foi estabelecida. O ac\u00famulo cerebral de \n\nganglios\u00eddeo GM2 e ganglios\u00eddeo GM3 (GM2 e GM3, respectivamente) est\u00e1 \n\nassociado \u00e0 neuropatologia de diversas doen\u00e7as, alterando o reconhecimento \n\n\n\n \n\n15 \n\n \n\ncelular na sinaptog\u00eanese e promovendo a apoptose celular (WALKLEY et al., \n\n1991). Na MPS I, o ac\u00famulo desses ganglios\u00eddeos \u00e9 um marcador do processo \n\nneurodegenerativo (CONSTANTOPOULOS et al., 1980; \n\nCONSTANTOPOULOS et al., 1985; RUSSELL et al., 1998), aumentando \n\nquantitativamente conforme a progress\u00e3o e a gravidade da doen\u00e7a. \n\n Nas LSD, a morte neuronal geralmente ocorre nos est\u00e1gios finais e n\u00e3o \n\nexplica per se o comprometimento do SNC. Nos est\u00e1gios iniciais da doen\u00e7a, a \n\nmorte das c\u00e9lulas de Purkinje do cerebelo constitui uma exce\u00e7\u00e3o \n\n(JEYAKUMAR et al., 2005) e foi observada nas doen\u00e7as de Niemann-Pick do \n\ntipo C (NPC) (WALKLEY, 2004), de Sandhoff (WADA et al., 2000) de Gaucher \n\ne MPS I (RUSSELL et al., 1998) E. Neufeld (comunica\u00e7\u00e3o pessoal). \n\n Os glicosaminoglicanos influenciam a forma\u00e7\u00e3o de placas senis e est\u00e3o \n\nenvolvidos na patog\u00eanese da doen\u00e7a de Alzheimer (BAHR &amp; BENDISKE, 2002; \n\nVAN HORSSEN et al., 2003). Em um estudo post mortem, GINSBERG et al. \n\n(1999) avaliaram a exist\u00eancia de placas senis em pacientes portadores de MPS \n\nI. Embora os achados tenham sido negativos, verificou-se um aumento na \n\nconcentra\u00e7\u00e3o do pept\u00eddeo beta-amil\u00f3ide sol\u00favel no citosol dos neur\u00f4nios. Esse \n\npept\u00eddeo \u00e9 considerado central na etiologia da doen\u00e7a de Alzheimer, existindo \n\na possibilidade de ser uma rota secund\u00e1ria de dano cerebral na MPS I. \n\n O desequil\u00edbrio na homeostase do c\u00e1lcio est\u00e1 associado \u00e0 \n\nneuropatologia de algumas LSD, como a doen\u00e7a de Gaucher, a doen\u00e7a de \n\nSandhoff (PELLED et al., 2003) e a mucolipidose do tipo IV (LAPLANTE et al., \n\n2002). Possivelmente, a aus\u00eancia de equil\u00edbrio do c\u00e1lcio no SNC seja um dos \n\n\n\n \n\n16 \n\n \n\nfatores contribuintes para a neuropatologia das MPS. Contudo, at\u00e9 o presente \n\nmomento, nenhum estudo foi realizado enfocando essa instabilidade na MPS I. \n\n Consider\u00e1vel aten\u00e7\u00e3o tem sido dada \u00e0 inflama\u00e7\u00e3o no SNC e ao seu \n\npapel na neurodegenera\u00e7\u00e3o nas LSD. O processo inflamat\u00f3rio cerebral j\u00e1 foi \n\nencontrado em diferentes LSD: nas gangliodisoses GM3 (WADA et al., 2000; \n\nMYEROWITZ et al., 2002; JEYAKUMAR et al., 2003) e GM2 (JEYAKUMAR et \n\nal., 2003), na doen\u00e7a de NPC (BAUDRY et al., 2003), na doen\u00e7a de Krabe \n\n(PEDCHENKO &amp; LEVINE, 1999) e nas MPS do tipo I e III (OHMI et al., 2003). \n\n O processo inflamat\u00f3rio \u00e9 mediado pelas c\u00e9lulas do Sistema \n\nImunol\u00f3gico. Essas c\u00e9lulas apresentam um sistema lisossomal bem \n\ndesenvolvido, estando frequentemente afetadas nas LSD (AULA et al., 1975; \n\nBRUCK et al., 1991; KIESEIER et al., 1997). JEYAKUMAR et al. (2005) \n\npropuseram ser a libera\u00e7\u00e3o de radicais livres e citocinas decorrente da \n\ndisfun\u00e7\u00e3o das c\u00e9lulas da microglia uma das causas do dano cerebral presente \n\nnessas doen\u00e7as. Tratamentos com antioxidantes abrandaram a sintomatologia \n\nde algumas LSD (BASCUNAN-CASTILLO et al., 2004), sugerindo uma \n\ninflu\u00eancia do desequil\u00edbrio oxidativo nessas patologias. \n\n O estudo das LSD obteve um grande avan\u00e7o devido ao uso de modelos \n\nanimais (NEUFELD &amp; MUENZER, 2001). No nosso estudo, utilizou-se o \n\nmodelo de OHMI et al. (2003), que inativaram o gene da ?-L-iduronidase (Idua) \n\npela inser\u00e7\u00e3o do gene de resist\u00eancia \u00e0 canamicina. Os animais homozigotos \n\npara a disrup\u00e7\u00e3o do gene (animais Idua\n-/-\n\n) n\u00e3o possuem atividade alguma da \n\nreferida enzima, tornando-os o modelo murino da s\u00edndrome de Hurler. Esses \n\n\n\n \n\n17 \n\n \n\ncamundongos apresentam fen\u00f3tipo similar ao do modelo desenvolvido por \n\nCLARKE et al. (1997). \n\n O modelo murino da MPS I desenvolvido por CLARKE et al. (1997) exibe \n\nfen\u00f3tipo normal ao nascimento e aparecimento gradual das altera\u00e7\u00f5es \n\ncaracter\u00edsticas da patologia. Com quatro semanas de vida, os machos \n\nknockout (animais Idua\n-/-\n\n) podem ser diferenciados dos controles pelas \n\naltera\u00e7\u00f5es faciais e vertebrais. Modifica\u00e7\u00f5es histol\u00f3gicas na t\u00edbia s\u00e3o \n\nobservadas com seis semanas de idade e, com oito semanas, os animais \n\nmostram patas alteradas. As altera\u00e7\u00f5es faciais progridem lentamente, exibindo \n\nfen\u00f3tipo bem distingu\u00edvel \u00e0s 16 semanas de idade. Animais jovens locomovem-\n\nse normalmente, entretanto, os animais knockout s\u00e3o praticamente incapazes \n\nde locomover-se \u00e0s 40 semanas. Na idade de 57 semanas, observa-se a \n\ndisostose m\u00faltipla, fen\u00f3tipo similar ao dos pacientes portadores da s\u00edndrome de \n\nHurler.  \n\n No SNC dos animais Idua\n-/-\n\n, h\u00e1 aumento gradual da concentra\u00e7\u00e3o de \n\nGM2 e GM3. Ocorre tamb\u00e9m morte progressiva das c\u00e9lulas de Purkinje, com \n\ndeple\u00e7\u00e3o total na idade de 40 semanas. Durante toda a vida desses animais, \n\nobserva-se aumento da excre\u00e7\u00e3o de GAGs.  \n\n Os animais knockout atingem a idade adulta e sua sobrevida ultrapassa \n\nas 85 semanas. Essa diferen\u00e7a em rela\u00e7\u00e3o aos pacientes com s\u00edndrome de \n\nHurler, cuja morte ocorre na inf\u00e2ncia, pode ser devida a diversidades entre \n\nesp\u00e9cies com rela\u00e7\u00e3o ao ac\u00famulo dos GAGs, aos efeitos secund\u00e1rios desses \n\nac\u00famulos ou \u00e0 necessidade temporal para manifesta\u00e7\u00e3o dos sintomas. \n\n\n\n \n\n18 \n\n \n\nOBJETIVOS \n\n \n\n A inexist\u00eancia de estudos sobre par\u00e2metros neurocomportamentais do \n\nmodelo murino de MPS I capazes de avaliar sua fun\u00e7\u00e3o cognitiva motivou a \n\nrealiza\u00e7\u00e3o deste trabalho. O nosso objetivo foi analisar par\u00e2metros cognitivos \n\nque possam ser utilizados na avalia\u00e7\u00e3o de diferentes terapias e seus efeitos \n\nsobre o SNC. \n\n Evid\u00eancias do envolvimento de processo inflamat\u00f3rio e estresse \n\noxidativo levaram-nos a avaliar diferentes biomarcadores de estresse oxidativo \n\nno SNC, cora\u00e7\u00e3o, pulm\u00e3o, diafragma, f\u00edgado, rim e ba\u00e7o do modelo murino de \n\nMPS I. \n\n \n\n\n\n \n\n19 \n\n \n\nARTIGO 1 \n\n \n\n Artigo publicado na revista Brain Research: \n\n REOLON, G. K.; BRAGA, L. M.; CAMASSOLA, M.; LUFT, T.; \n\nHENRIQUES, J. A.; NARDI, N. B. &amp; ROESLER, R. Long-term memory for \n\naversive training is impaired in Idua(-/-) mice, a genetic model of \n\nmucopolysaccharidosis type I. Brain Research, 1076(1): 225-230, 2006. \n\n \n\n\n\nB R A I N R E S E A R C H 1 0 7 6 ( 2 0 0 6 ) 2 2 5 \u2013 2 3 0\n\navailable at www.sciencedirect.com\n\nwww.elsevier.com/locate/brainres\nResearch Report\n\nLong-term memory for aversive training is impaired in Idua?/?\n\nmice, a genetic model of mucopolysaccharidosis type I\nGustavo Kellermann Reolona,b, Luisa Macedo Bragac, Melissa Camassolac, Tatiana Lufta,\nJo\u00e3o Ant\u00f4nio P\u00eagas Henriquesb,d, Nance Beyer Nardic, Rafael Roeslera,b,?\naCellular and Molecular Pharmacology Research Group, Department of Pharmacology, Institute for Basic Health Sciences,\nFederal University of Rio Grande do Sul, 90046-900 Porto Alegre, RS, Brazil\nbGraduate Program in Cellular and Molecular Biology, Center for Biotechnology, Federal University of Rio Grande do Sul,\n91501-970 Porto Alegre, RS, Brazil\ncImmunogenetics Laboratory, Department of Genetics, Institute for Biosciences, Federal University of Rio Grande do Sul,\n91540-000 Porto Alegre, RS, Brazil\ndSchool of Pharmacy, Lutheran University of Brazil, 92420-280 Canoas, RS, Brazil\nA R T I C L E I N F O\n? Corresponding author. Department of Pharm\nSarmento Leite, 500, Campus Central/UFRGS\n\nE-mail address: rroesler@terra.com.br (R.\n\n0006-8993/$ \u2013 see front matter \u00a9 2006 Elsevi\ndoi:10.1016/j.brainres.2006.01.008\nA B S T R A C T\nArticle history:\nAccepted 3 January 2006\nAvailable online 13 February 2006\nMucopolysaccharidosis type I (MPS I) is a lysosomal storage disease that leads to\nneurodegeneration and neurological deficits, among other pathological and clinical\nconsequences. The aim of the present study was to evaluate neurobehavioral parameters\nin a genetic mouse model of mucopolysaccharidosis type I (MPS I). During exploration of an\nopen field, adult MPS I (Idua?/?) mice showed normal locomotion and anxiety but reduced\nnumber of rearings. Idua?/? mice performed normally in a novel object recognition memory\ntask and showed normal short-term retention of inhibitory avoidance training. By contrast,\nlong-term retention of inhibitory avoidance was impaired in Idua?/? mice. The deficit in\ninhibitory avoidance memory could not be attributed to reduced footshock reactivity. The\nresults indicate that Idua?/? mice present deficits in long-term memory for aversive training\nand reduced exploratory behavior.\n\n\u00a9 2006 Elsevier B.V. All rights reserved.\nKeywords:\nMucopolysaccharidosis type I\nLysosomal storage disease\nMPS mouse model\nNeural plasticity\nMemory\nBehavior\n1. Introduction\n\nMucopolysaccharidosis type I (MPS I) is a heritable lysosomal\nstorage disease resulting from a deficiency of alpha-L-idur-\nonidase, the enzyme required for degradation of glycosami-\nnoglycans (GAGs) dermatan sulfate and heparin sulfate. In\naffected children, mutations in the IDUA gene lead to GAG\naccumulation in lysosomes, tissue pathology, and severe\nclinical features including growth delay, altered facial fea-\ntures, skeletal abnormalities, hepatosplenomegaly, and cen-\nacology, Institute for Ba\n, 90046-900 Porto Alegre,\nRoesler).\n\ner B.V. All rights reserved\ntral nervous system (CNS) deficits (Scriver, 2001). Neu\nrodegeneration, severe mental retardation and death in\nchildhood are seen in the most severe phenotype of MPS I,\nHurler syndrome, which results from homozygosity for some\nmutations in the IDUA gene (Scott et al., 1995; Scriver, 2001).\n\nThe availability of a genetic mouse model of MPS I (Idua?/?)\nmakes it possible to investigate the neurological deficits\nassociated with MPS I (Clarke et al., 1997; Ohmi et al., 2003;\nHartung et al., 2004). A previous study has suggested that\nIdua?/? mice show impaired memory assessed in an open field\nsic Health Sciences, Federal University of Rio Grande do Sul, Rua\nRS, Brazil. Fax: +55 51 3316 3121.\n\n.\n\nmailto:rroesler@terra.com.br\nhttp://dx.doi.org/10.1016/j.brainres.2006.01.008\n\n\n226 B R A I N R E S E A R C H 1 0 7 6 ( 2 0 0 6 ) 2 2 5 \u2013 2 3 0\nhabituation paradigm (Hartung et al., 2004). In addition,\ncognitive deficits have been observed in mouse models of\nother types of lysosomal storage disease. For instance, MPS VII\nshow impaired spatial memory (Chang et al., 1993; Frisella et\nal., 2001). However, a detailed behavioral analysis of Idua?/?\n\nmice has not been previously reported. In the present study,\nwe investigated open field behavior, memory for aversive\ntraining, and recognition memory in Idua?/? mice. Develop-\nmental and metabolic features of Idua?/? mice have been\ndescribed elsewhere (Hartung et al., 2004).\n2. Results\n\n2.1. Open field behavior\n\nResults for open field behavior are shown in Fig. 1. There were\nno significant differences between groups in the latency to\nstart locomotion (P = 0.93; Fig. 1A), number of crossings\nperformed (P = 0.24; Fig. 1B), or defecation (P = 0.43; Fig. 1D)\nindicating that Idua?/? mice showed no alterations in locomo-\ntion or anxiety. However, Idua?/? mice showed a significantly\nlower number of rearings, which indicates reduced explorato-\nry behavior, compared to control animals (P b 0.05; Fig. 1C).\n\n2.2. Novel object recognition\n\nIn the recognition memory task, there was no difference\nbetween groups in the total time spent exploring both objects\nduring the training trial, indicating that both groups showed\nsimilar locomotion and motivation during task acquisition.\nMean \u00b1 SE total exploration time (s) was 14.00 \u00b1 3.12 s in control\nmice and 13.10 \u00b1 1.98 s in Idua?/? animals (P = 0.81). In addition,\nthere was no significant difference between groups in explor-\natory preference in the training trial (P = 0.71) (Fig. 2A). There\nwerenosignificant differences betweengroupsin short (P = 0.55;\nFig. 1 \u2013 Open field behavior in Idua?/? and control mice. Animals\nmean \u00b1 SE (A) latency to start locomotion (s), (B) number of crossing\nanimals in the control group and 11 animals in the Idua?/? group\nFig. 2B)- or long-term (P = 0.66; Fig. 2C) memory retention of the\nobject recognition task. Both groups showed significant prefer-\nence towards the novel object during both the short- and long-\nterm retention test trials (both Ps b 0.01 in the short-term\nretention test trial and both Ps b 0.05 in the long-term retention\ntest trial). These findings indicate that Idua?/? mice showed no\nalterations in novel object recognition memory.\n\n2.3. Inhibitory avoidance\n\nResults for inhibitory avoidance are shown in Fig. 3. There\nwere no significant differences between groups in training\ntrial performances (P = 0.75; mean \u00b1 SE overall training trial\nstep-down latencies was 9.04 \u00b1 4.01 s). There was no\nsignificant difference between groups in short-term inhibitory\navoidance retention (P = 0.96) (Fig. 3A). However, Idua?/? mice\nshowed impaired long-term retention when compared to the\ncontrol group (P b 0.01) (Fig. 3B). These results indicate that\nIdua?/? mice showed impaired long-term memory for inhibi-\ntory avoidance training.\n\n2.4. Footshock reactivity\n\nThere was no significant difference between groups in\nreactivity to the footshock assessed by flinch (Fig. 4A) and\njump (Fig. 4B) thresholds (Ps = 1.00 and 0.11 for flinch and jump\nthresholds respectively), indicating that Idua?/? mice showed\nno alterations in nociception.\n3. Discussion\n\nThe main result of the present study is that Idua?/? mice, a\nmouse model of MPS I, showed impaired long-term memory of\ninhibitory avoidance, a type of single-trial aversively motiva-\nted conditioning, whereas no alterations were observed in\nwere left to freely explore the arena for 5 min. Data are\ns, (C) number of rearings, and (D) number of fecal pellets. N = 9\n\n. *Significant difference from the control group (P b 0.05).\n\n\n\nFig. 2 \u2013 Novel object recognition memory in Idua?/? and\ncontrol mice. Memory retention was tested at 1.5 h\n(short-term memory retention) or 24 h (long-term memory\nretention) after training. Data are median (interquartile\nranges) exploratory preferences during the (A) training, (B)\nshort-term retention test, or (C) long-term retention test\ntrials. Exploratory preference was defined as % time\nexploring object A2 during training or % time exploring the\nnovel objects B and C during short- and long-term retention\ntest trials). N = 9 animals in the control group and 11 animals\nin the Idua?/? group. There was no significant difference\nbetween groups.\n\nFig. 3 \u2013 Memory for inhibitory avoidance training in Idua?/?\n\nand control mice. Memory retention was tested at (A)\n1.5 h (short-term memory retention) or (B) 24 h (long-term\nmemory retention) after training. Data are median\n(interquartile ranges) retention test latencies to step-down.\nN = 8 animals per group. **Significant difference from the\ncontrol group (P b 0.01).\n\n227B R A I N R E S E A R C H 1 0 7 6 ( 2 0 0 6 ) 2 2 5 \u2013 2 3 0\nshort-term inhibitory avoidance retention or novel object\nrecognition memory. In addition, Idua?/? animals showed\nnormal locomotion and anxiety but reduced exploratory\nbehavior assessed during exploration of an open field. Because\nIdua?/? mice showed normal short-term retention of inhibitory\navoidance and no alterations in footshock reactivity, the\ndeficit in long-term inhibitory avoidance memory could not\nbe attributed to alterations in nociception or other sensori-\nmotor functions.\n\nThe clinical manifestations of MPS I include a range of\nneurological deficits. Severe mental retardation, neurodegen-\neration, and death in childhood are observed in Hurler\nsyndrome, the most severe form of MPS I (Scott et al., 1995).\nOther types of MPS (for instance, MPS IIIB) are also associated\nwith severe CNS dysfunction and neurodegeneration (Scott et\nal., 1995; Scriver, 2001). Idua?/? mice provide a mouse model of\nMPS I that makes it possible to characterizefunctionaldeficits in\ndifferent rodent models of neurological function and evaluate\nthe potential protective effects of experimental therapeutic\napproaches against the neurological deficits associated with\nMPS I (Clarke et al., 1997; Ohmi et al., 2003; Hartung et al., 2004).\n\nA previous study (Hartung et al., 2004) has described\nseveral abnormalities in Idua?/? mice, including higher levels\nof urinary GAG and GAG lysosomal storage, increased body\nweight, and craniofacial abnormalities. The only measure of\nneurological function investigated in that study was habitu-\nation, a type of nonaversive, nonassociative memory (Vianna\net al., 2000), in which Idua?/? mice showed impaired perfor-\nmance when compared to controls. In contrast, our findings\nindicate that Idua?/? mice showed impaired memory for\naversively motivated training, whereas memory for a non-\naversive task was normal. The mechanisms underlying the\ndifferential ability of Idua?/? mice to learn memories for\ndifferent types of tasks remain to be determined. Formation\nof long-term memory for aversively motivated memory tasks\nsuch as inhibitory avoidance is importantly influenced by the\nrelease of hormones and neurotransmitters associated with\n\n\n\nFig. 4 \u2013 Footshock reactivity in Idua?/? and control mice. Data\nare means \u00b1 SE (A) flinch and (B) jump thresholds (mA). N = 7\nanimals per group. There was no significant difference\nbetween groups.\n\n228 B R A I N R E S E A R C H 1 0 7 6 ( 2 0 0 6 ) 2 2 5 \u2013 2 3 0\nexposure to emotional events, and the basolateral amygdala\nis a critical brain area mediating these modulatory influences\non long-term memory consolidation (for a review, see\nMcGaugh (2000)). Thus, it is possible that alterations in\nhormonal responses to stressful events and/or changes in\namygdala function are involved in the selective impairment\nof long-term aversive memory in Idua?/? mice observed in the\npresent study. Memory function has also been investigated in\nother mouse models of lysosomal storage diseases. Thus,\nMPS VII mice show impaired spatial memory assessed either\nin the Morris water maze (Chang et al., 1993; Frisella et al.,\n2001) or in a reward learning protocol (Brooks et al., 2002). In a\nmouse model of Niemann-Pick type C disease, knockout\nanimals showed reduced exploratory behavior and impair-\nments of spatial memory and habituation (V\u00f5ikar et al., 2002).\nEvaluating memory function in a mouse model of metachro-\nmatic leukodystrophy (MLD), Consiglio et al. (2001) observed\nthat MLD mice showed impaired memory in a radial arm\nmaze task and a nonsignificant reduction in performance in\ninhibitory avoidance and active avoidance tasks. Our finding\nthat Idua?/? mice show impaired long-term inhibitory avoid-\nance memory indicates that aversively motivated mouse\nmodels of learning and memory can be used for the\ncharacterization of neurological deficits associated with\nthose diseases as well as for the evaluation of the effects of\npotential novel therapeutics.\n\nFurther research is necessary to investigate the neuro-\nchemical and neuropathological alterations mediating the\nselective dysfunction of long-term aversive memory in Idua?/?\n\nmice observed in the present study. Although both short- and\nlong-term memory for inhibitory avoidance depend on the\nfunctional integrity of the dorsal hippocampus (Izquierdo and\nMedina, 1997; McGaugh, 2000; Roesler et al., 2003; Quevedo et\nal., 2004), formation of these types of memory is mediated by\ndifferent neurochemical mechanisms. For instance, consoli-\ndation of long- but not short-term memory for inhibitory\navoidance is disrupted by intrahippocampal administration\nof a protein synthesis inhibitor (Quevedo et al., 2004).\nPrevious studies have indicated that the cognitive deficits\nassociated with mouse models of heritable lysosomal storage\ndiseases are at least partially mediated by dysfunction of\nhippocampal neurons. Thus, MLD mice show selective\ndegeneration of pyramidal cells in the dorsal hippocampus,\nand in vivo gene therapy using lentiviral vectors protects\nagainst both the degeneration of hippocampal neurons and\nmemory deficits in that model (Consiglio et al., 2001). An\ninflammatory component associated with microglia activa-\ntion in cortical areas is also likely to mediate cognitive\ndeficits in the Idua?/? MPS I mouse model (Ohmi et al., 2003).\nFurther studies aiming at examine alterations in synaptic\ntransmission and cellular signaling pathways at the hippo-\ncampus and other brain areas in animal models as well as\npatients are necessary to increase our understanding of the\nmechanisms underlying cognitive deficits associated with\nlysosomal storage diseases.\n\nIn summary, our results show a specific impairment of\naversively motivated memory and reduced exploratory be-\nhavior in Idua?/? mice, a genetic model of MPS I. Future studies\ncould use aversive memory tasks to evaluate the potential\nprotective effect of experimental therapeutic approaches\nagainst cognitive deficits in mouse models of MPS.\n4. Experimental procedures\n\n4.1. Animals\n\nEighteen adult male C57-BL6 Idua?/? mice (153\u2013208 days of age\nand mean body weight of 26.68 g at the date of first\nexperiment) were used as experimental subjects. It has been\npreviously shown that Idua?/? mice with 5 months of age show\nlysosomal storage in a number of tissues, increased urinary\nGAG levels, craniofacial abnormalities, increased body weight,\nand impaired habituation (Hartung et al., 2004). Sixteen adult\nmale wild-type C57-BL6 inbred mice (155\u2013202 days of age and\nmean body weight of 23.04 g at the date of first experiment)\nwere used as controls. Idua?/? mice produced by targeted\ndisruption of the murine IDUA gene (Clarke et al., 1997; Ohmi\net al., 2003; Hartung et al., 2004) were derived from animals\nkindly provided by Dr. Elizabeth Neufeld (University of\nCalifornia, Los Angeles, CA). Homozygous mutants were\nidentified at the 21st day of life by polymerase chain reaction\n(Clarke et al., 1997; Hartung et al., 2004). Animals were\nmaintained on a 12-h light/dark cycle with food and water\navailable ad libitum. Brothers and sisters were bred, and the\ncolony was maintained by mating of heterozygotes. Experi-\nments were conducted in homozygotes KO (?/?) and normal\nhomozygotes (+/+) were used as controls. Behavioral proce-\ndures were conducted between 9:00 and 17:30. All experimen-\ntal procedures were in accordance with the NIH Guide for Care\nand Use of Laboratory Animals (NIH publication No. 85-23\n\n\n\n229B R A I N R E S E A R C H 1 0 7 6 ( 2 0 0 6 ) 2 2 5 \u2013 2 3 0\nrevised 1996) and the procedures of the Brazilian College of\nLaboratory Animals (COBEA).\n\n4.2. Behavioral testing\n\nThe same animals (9 control and 11 Idua?/? mice) were used in\nthree different behavioral tests. They were submitted first to\nopen field exploration (Roesler et al., 1999b), followed by a\nnovel object recognition task (Rosa et al., 2003) carried out in\nthe same open field arena 1 day later. Finally, animals were\ntrained and tested in a single-trial step-down inhibitory\navoidance task (Roesler et al., 1999b) 1 week after the end of\nthe recognition memory test. Four animals (1 control mouse\nand 3 Idua?/? mice) were removed from the inhibitory\navoidance experiment because animals failed to step down\nfrom the platform within 60 s during the training trial. Another\ngroup of mice (7 control and 7 Idua?/? mice) were subsequently\nused for a footshock reactivity test.\n\n4.2.1. Open field behavior\nOpen field exploration was carried out as previously described\n(Roesler et al., 1999b). The open field was a 50 \u00d7 25-cm arena,\nsurrounded by 50-cm high walls, made of brown plywood with\na frontal glass wall. The floor of the arena was divided into 12\nequal squares by black lines. Mice were put in the apparatus,\nplaced on its left rear quadrant, and left to freely explore the\narena for 5 min. Crossings of the black lines, rearings\nperformed, latency to start locomotion, and the number of\nfecal pellets were counted. The number of crossings and\nrearings was used respectively as measures of locomotor\nactivity and exploratory behavior, whereas the latency to start\nlocomotion and the number of fecal pellets were used as\nmeasures of anxiety (Roesler et al., 1999b; Fernandez-Teruel et\nal., 2002; Henderson et al., 2004; Singer et al., 2005).\n\n4.2.2. Novel object recognition\nThe object recognition task is a nonspatial, nonaversive\nmemory test which has been shown to be a useful experi-\nmental tool for assessing changes in brain function in mouse\ngenetic models (Tang et al., 1999; Rampon et al., 2000). The\nnovel object recognition task was performed as previously\ndescribed (Rosa et al., 2003). Training in the object recognition\ntask took place in the same arena used for the open field, thus\nthe open field exploration trial was used as a habituation trial\nfor the recognition memory task. Twenty-four hours after\narena exploration, training was conducted by placing individ-\nual mice for 5 min into the arena, in which two identical\nobjects (objects A1 and A2; Duplo Lego toys) were positioned in\ntwo adjacent corners, 10 cm from the walls. In a short-term\nmemory retention test given 1.5 h after training, the mice\nexplored the open field for 5 min in the presence of one\nfamiliar (A) and one novel (B) object. All objects presented\nsimilar textures, colors, and sizes, but distinctive shapes. The\nexploratory preference was defined as percentage of the total\nexploration time that the animal spent investigating object A2\n(in the training trial) or the novel object (in short- and long-\nterm retention test trials). Differences in exploratory prefer-\nences between training and retention test trials were used as\nmemory retention scores. Between trials the objects were\nwashed with 10% ethanol solution. In a long-term memory\nretention test given 24 h after training, the same mice\nexplored the field for 5 min in the presence of familiar object\nA and a novel object C. Recognition memory was evaluated as\nfor the short-term memory test. Exploration was defined as\nsniffing or touching the object with the nose and/or forepaws.\n\n4.2.3. Inhibitory avoidance\nInhibitory avoidance in rodents is a widely used animal model\nof aversively motivated learning and memory (for reviews, see\nIzquierdo and Medina, 1997; McGaugh 2000). The step-down\ninhibitory avoidance apparatus and procedures were de-\nscribed in a previous study (Roesler et al., 1999b). The\ninhibitory avoidance training box was a 50 \u00d7 25 \u00d7 25-cm\nacrylic box whose floor consisted of parallel stainless steel\nbars (1 mm diameter) spaced 1 cm apart. A 10-cm2 wide, 2-cm\nhigh platform was placed on the center of the floor. Animals\nwere placed on the platform, and their latency to step-down\non the grid with all four paws was recorded with an automated\ndevice. In the training trial, immediately after stepping down\non the grid, animals were given a 0.4 mA, 2.0 s footshock. In\nretention test sessions, carried out 1.5 h (short-term memory\nretention) and 24 h (long-term memory retention) after\ntraining, no footshocks were given and a ceiling of 180 s was\nimposed in the step-down latency. The differences between\nretention test and training trial step-down latencies were used\nas memory retention scores.\n\n4.2.4. Footshock reactivity\nA control experiment evaluating the animals' reactivity to the\nfootshock was carried out in the same apparatus used for\ninhibitory avoidance as described in previous studies (Roesler\net al., 1999a, 2000). Briefly, the platform was removed, and\neach animal was placed on the grid and allowed a 1-min\nhabituation period prior to the start of a series of footshocks\n(0.5 s) delivered at 10-s intervals. Shock intensities ranged\nfrom 0.1 to 0.8 mA in 0.1-mA increments. The adjustments in\nshock intensity were made in accordance to each animal's\nresponse. Shock intensity was raised by 1 U when no response\noccurred and lowered by 1 U when a response was made. A\n\u201cflinch\u201d response was defined as withdrawal of one paw from\nthe grid floor, and a \u201cjump\u201d response was defined as a rapid\nwithdrawal of three or four paws. Two measurements of the\n\u201cflinch\u201d threshold were made, and then two measures of the\n\u201cjump\u201d threshold were made. For each animal, the mean of\nthe two scores for the flinch and jump thresholds was\nconsidered.\n\n4.3. Statistics\n\nData for inhibitory avoidance retention test latencies and\nexploratory preferences in the object recognition task are\nshown as median (interquartile ranges). Using nonparametric\nstatistics is preferred for the analysis of data for memory tasks\nsuch as inhibitory avoidance because a ceiling is imposed in\nretention test trials (Roesler et al., 1999a,b, 2000, 2003; Rosa et\nal., 2003; Quevedo et al., 2004). Comparisons between groups\nwere performed using Mann\u2013Whitney U tests, two-tailed.\nComparisons between trials within the same group were done\nusing Wilcoxon tests. Data for open field behavior, inhibitory\navoidance training trial latencies, and nociceptive thresholds\n\n\n\n230 B R A I N R E S E A R C H 1 0 7 6 ( 2 0 0 6 ) 2 2 5 \u2013 2 3 0\nare shown as mean \u00b1 SE (Roesler et al., 1999b, 2000).\nComparisons between groups were performed using unpaired\nStudent t tests. In all comparisons, P values of less than 0.05\nwere considered to indicate statistical significance.\nAcknowledgments\n\nThis research was supported by the Millennium Institute of\nGene Therapy (CNPq-MCT grant 420036/2005-9), FAPERGS-RS,\nPROPESQ-UFRGS, and the South American Office for Antican-\ncer Drug Development. G.K.R. is a recipient of a CAPES-MEC\nfellowship. Authors thank Dr. Elizabeth F. Neufeld for her\ngenerous gift of Idua?/? mice.\nR E F E R E N C E S\n\nBrooks, A.I., Stein, C.S., Hughes, S.M., Heth, J., McCray, P.M., Sauter,\nS.L., Johnston, J.C., Cory-Slechta, D.A., Federoff, H.J., Davidson,\nB.L., 2002. Functional correction of established central nervous\nsystem deficits in an animal model of lysosomal storage\ndisease with feline immunodeficiency virus-based vectors.\nProc. Natl. Acad. Sci. U. S. A. 99, 6216\u20136221.\n\nChang, P.L., Lambert, D.T., Pisa, M.A., 1993. Behavioural\nabnormalities in a murine model of a human lysosomal\nstorage disease. NeuroReport 4, 507\u2013510.\n\nClarke, L.A., Russell, C.S., Pownall, S., Warrington, C.L., Borowski,\nA., Dimmick, J.E., Toone, J., Jirik, F.R., 1997. Murine\nmucopolysaccharidosis type I: targeted disruption of the\nmurine alpha-L-iduronidase gene. Hum. Mol. Genet. 6, 503\u2013511.\n\nConsiglio, A., Quattrini, A., Martino, S., Bensadoun, J.C., Dolcetta,\nD., Trojani, A., Benaglia, G., Marchesini, S., Cestari, V., Oliverio,\nA., Bordignon, C., Naldini, L., 2001. In vivo gene therapy of\nmetachromatic leukodystrophy by lentiviral vectors:\ncorrection of neuropathology and protection against learning\nimpairments in affected mice. Nat. Med. 7, 310\u2013316.\n\nFernandez-Teruel, A., Escorihuela, R.M., Gray, J.A., Aguilar, R., Gil,\nL., Gimenez-Llort, L., Tobena, A., Bhomra, A., Nicod, A., Mott, R.,\nDriscoll, P., Dawson, G.R., Flint, J., 2002. A quantitative trait\nlocus influencing anxiety in the laboratory rat. Genome Res. 12,\n618\u2013626.\n\nFrisella, W.A., O'Connor, L.H., Vogler, C.A., Roberts, M., Walkley, S.,\nLevy, B., Daly, T.M., Sands, M.S., 2001. Intracranial injection of\nrecombinant adeno-associated virus improves cognitive\nfunction in a murine model of mucopolysaccharidosis type VII.\nMol. Ther. 3, 351\u2013358.\n\nHartung, S.D., Frandsen, J.L., Pan, D., Koniar, B.L., Graupman, P.,\nGunther, R., Low, W.C., Whitley, C.B., McIvor, R.S., 2004.\nCorrection of metabolic, craniofacial, and neurologic\nabnormalities in MPS I mice treated at birth with adeno-\nassociated virus vector transducing the human alfa-l-\niduronidase gene. Mol. Ther. 9, 866\u2013875.\n\nHenderson, N.D., Turri, M.G., DeFries, J.C., Flint, J., 2004. QTL\nanalysis of multiple behavioral measures of anxiety in mice.\nBehav. Genet. 34, 267\u2013293.\n\nIzquierdo, I., Medina, J.H., 1997. Memory formation: the sequence\nof biochemical events in the hippocampus and its connection\nto activity in other brain structures. Neurobiol. Learn. Mem. 68,\n285\u2013316.\n\nMcGaugh, J.L., 2000. Memory\u2014A century of consolidation. Science\n287, 248\u2013251.\n\nOhmi, K., Greenberg, D.S., Rajavel, K.S., Ryazantsev, S., Li, H.H.,\nNeufeld, E.F., 2003. Activated microglia in cortex of mouse\nmodels of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad.\nSci. U. S. A. 100, 1902\u20131907.\n\nQuevedo, J., Vianna, M.R., Martins, M.R., Barichello, T., Medina, J.H.,\nRoesler, R., Izquierdo, I., 2004. Protein synthesis, PKA, and MAP\nkinase are differentially involved in short- and long-term\nmemory in rats. Behav. Brain Res. 154, 339\u2013343.\n\nRampon, C., Tang, Y.P., Goodhouse, J., Shimizu, E., Kyin, M., Tsien,\nJ.Z., 2000. Enrichment induces structural changes and recovery\nfrom nonspatial memory deficits in CA1 NMDAR1-knockout\nmice. Nat. Neurosci. 3, 238\u2013244.\n\nRoesler, R., Vianna, M.R., de-Paris, F., Quevedo, J., 1999a.\nMemory-enhancing treatments do not reverse the\nimpairment of inhibitory avoidance retention induced by\nNMDA receptor blockade. Neurobiol. Learn. Mem. 72, 252\u2013258.\n\nRoesler, R., Walz, R., Quevedo, J., de Paris, F., Zanata, S.M., Graner,\nE., Izquierdo, I., Martins, V.R., Brentani, R.R., 1999b. Normal\ninhibitory avoidance learning and anxiety, but increased\nlocomotor activity in mice devoid of PrPc. Mol. Brain Res. 71,\n349\u2013353.\n\nRoesler, R., Vianna, M.R., de-Paris, F., Rodrigues, C., Sant'Anna,\nM.K., Quevedo, J., Ferreira, M.B., 2000. NMDA receptor\nantagonism in the basolateral amygdala blocks enhancement\nof inhibitory avoidance learning in previously trained rats.\nBehav. Brain Res. 112, 99\u2013105.\n\nRoesler, R., Schr\u00f6der, N., Vianna, M.R., Quevedo, J., Bromberg, E.,\nKapczinski, F., Ferreira, M.B., 2003. Differential involvement of\nhippocampal and amygdalar NMDA receptors in contextual\nand aversive aspects of inhibitory avoidance memory in rats.\nBrain Res. 975, 207\u2013213.\n\nRosa, R.M., Flores, D.G., Appelt, H.R., Braga, A.L., Henriques, J.A.,\nRoesler, R., 2003. Facilitation of long-term object recognition\nmemory by pretraining administration of diphenyl diselenide\nin mice. Neurosci. Lett. 341, 217\u2013220.\n\nScott, H.S., Bunge, S., Gal, A., Clarke, L.A., Morris, C.P., Hopwood,\nJ.J., 1995. Molecular genetics of mucopolysaccharidosis type I:\ndiagnostic, clinical, and biological implications. Hum. Mutat.\n6, 288\u2013302.\n\nScriver, C.R.E.A., 2001. The Metabolic and Molecular Bases of\nInherited Diseases. McGraw-Hill, New York.\n\nSinger, J.B., Hill, A.E., Nadeau, J.H., Lander, E.S., 2005. Mapping\nquantitative trait loci for anxiety in chromosome substitution\nstrains of mice. Genetics 169, 855\u2013862.\n\nTang, Y.P., Shimizu, E., Dube, G.R., Rampon, C., Kerchner, G.A.,\nZhuo, M., Liu, G., Tsien, J.Z., 1999. Genetic enhancement of\nlearning and memory in mice. Nature 401, 63\u201369.\n\nVianna, M.R., Alonso, M., Viola, H., Quevedo, J., de Paris, F.,\nFurman, M., de Stein, M.L., Medina, J.H., Izquierdo, I., 2000. Role\nof hippocampal signaling pathways in long-term memory\nformation of a nonassociative learning task in the rat. Learn.\nMem. 7, 333\u2013340.\n\nV\u00f5ikar, V., Rauvala, H., Ikonen, E., 2002. Cognitive deficit and\ndevelopment of motor impairment in a mouse model of\nNiemann-Pick type C disease. Behav. Brain Res. 132, 1\u201310.\n\n\n\n26 \n \n\nARTIGO 2 \n\n \n\n Artigo publicado na revista Cellular and Molecular Neurobiology.:  \n\n REOLON, G. K.; REINKE, A.; DE OLIVEIRA, M. R.; BRAGA, L. M.; \n\nCAMASSOLA, M.; ANDRADES, M. E.; MOREIRA, J. C.; NARDI, N. B.; \n\nROESLER, R.; DAL-PIZZOL, F. Alterations in oxidative markers in the \n\ncerebellum and peripheral organs in MPS I mice. Cellular and Molecular \n\nNeurobiology, 29(4): 443-448, 2009. \n\n \n\n\n\nO R I G I N A L P A P E R\n\nAlterations in Oxidative Markers in the Cerebellum\nand Peripheral Organs in MPS I Mice\n\nGustavo Kellermann Reolon \u00c6 Adalisa Reinke \u00c6 Marcos Roberto de Oliveira \u00c6\nLuisa Macedo Braga \u00c6 Melissa Camassola \u00c6 Michael E?verton Andrades \u00c6\nJose? Cla?udio Fonseca Moreira \u00c6 Nance Beyer Nardi \u00c6 Rafael Roesler \u00c6\nFelipe Dal-Pizzol\n\nReceived: 12 May 2008 / Accepted: 27 November 2008 / Published online: 25 December 2008\n\n? Springer Science+Business Media, LLC 2008\n\nAbstract Mucopolysaccharidosis type I is a lysosomal\n\nstorage disease with alterations in several organs. Little is\n\nknown about the pathways that lead to the pathology. Evi-\n\ndences point oxidative stress on lysosomal storage diseases\n\nand mucopolysaccharidosis type I. The aim of the present\n\nstudy was to evaluate oxidative biomarkers on mucopoly-\n\nsaccharidosis type I mice model. We evaluated antioxidant\n\nenzymatic activity, protein damage and lipid peroxidation\n\nin the forebrain, cerebellum, heart, lung, diaphragm, liver,\n\nkidney and spleen. Superoxide dismutase activity was\n\nincreased on cerebellum, lung, diaphragm, liver and kidney\n\nof mucopolysaccharidosis type I mice. Catalase activity was\n\nincreased on cerebellum, spleen and lung. There was no\n\nalteration on glutathione peroxidase activity on any of the\n\nanalyzed organs. Mucopolysaccharidosis type I mice\n\nshowed increased carbonyl groups on cerebellum, heart and\n\nspleen. There was a decrease of thiobarbituric acid-reactive\n\nsubstances on the cerebellum of mucopolysaccharidosis\n\ntype I mice. The results indicate a oxidative imbalance in\n\nthis model. As lysosomes are very susceptible to oxidative\n\ndamage, leading inclusive to cellular death, and lysosomal\n\nstorage diseases present several alterations on this organ-\n\nelles, this finding can help to elucidate the cellular damage\n\npathways on mucopolysaccharidosis type I.\n\nKeywords Mucopolysaccharidosis type I ?\nLysosomal storage diseases ? Oxidative stress ?\nGenetic mouse models\n\nAbbreviations\n\nCAT Catalase\n\nDNPH Dinitrophenylhydrazine\n\nGAG Glycosaminoglycans\n\nGPx Glutathione peroxidase\n\nGSH Glutathione\n\nIDUA a-L-iduronidase\nLSD Lysosomal storage diseases\n\nMDA Malondialdehyde\n\nMPS Mucopolysaccharidosis\n\nNADPH Nicotinamide adenine dinucleotide\n\nphosphate diaphorase\n\nRNS Reactive nitrogen species\n\nROS Reactive oxygen species\n\nSOD Superoxide dismutase\n\nTBARS Thiobarbituric acid-reactive substances\n\nTCA Trichloroacetic acid\n\nG. K. Reolon ? R. Roesler (&amp;)\nDepartment of Pharmacology, Cellular and Molecular\n\nNeuropharmacology Research Group, Institute for Basic\n\nHealth Sciences, and Cancer Research Laboratory,\n\nAcademic Hospital Research Center, Federal University\n\nof Rio Grande do Sul, Rua Sarmento Leite, 500, ICBS,\n\nCampus Centro/UFRGS, 90046-900 Porto Alegre, RS,\n\nBrazil\n\ne-mail: rroesler@terra.com.br\n\nA. Reinke ? F. Dal-Pizzol\nDepartment of Medicine, Laboratory of Physiopathology,\n\nUniversity of Southern Santa Catarina, 88806-000\n\nCriciu?ma, SC, Brazil\n\nM. R. de Oliveira ? M. E?. Andrades ? J. C. F. Moreira\nDepartment of Biochemistry, Center for Oxidative Stress\n\nResearch, Institute for Basic Health Sciences, Federal\n\nUniversity of Rio Grande do Sul, 90035-003 Porto Alegre,\n\nRS, Brazil\n\nL. M. Braga ? M. Camassola ? N. B. Nardi\nDepartment of Genetics, Immunogenetics Laboratory,\n\nInstitute for Biosciences, Federal University of Rio\n\nGrande do Sul, 91540-000 Porto Alegre, RS, Brazil\n\n123\n\nCell Mol Neurobiol (2009) 29:443\u2013448\n\nDOI 10.1007/s10571-008-9335-5\n\n\n\nIntroduction\n\nLysosomal storage diseases (LSD) are a group of inherited\n\nmetabolic disorders that share a common pathophysiology,\n\nin which a deficiency of enzymes catalyzing the stepwise\n\ndegradation of macromolecular substrate causes their\n\ngradual lysosomal accumulation. This accumulation even-\n\ntually results in cell, tissue and organ dysfunctions.\n\nMucopolysaccharidosis are LSD, the type I (MPS I) is\n\ncaused by deficiency of the enzyme a-L-iduronidase\n(IDUA), i.e., the lysosomal protein necessary to start the\n\nbreakdown of the glycosaminoglycans (GAGs) heparan\n\nsulfate and dermatan sulfate. Total loss of IDUA function\n\nresults in the worst phenotype, Hurler syndrome. There is\n\nan involvement of multiple organs, some symptoms are\n\ngrowth delay, hepatosplenomegaly, coarse facial features,\n\nexcessive urinary GAGs, skeletal abnormalities and neu-\n\nrodegeneration (Neufeld and Muenzer 1995).\n\nThe lysosomes in LSD increase in size and number in an\n\nattempt to retain the growing concentration of undegraded\n\nmaterial. This is well characterized as the primary cause of\n\nthe disease; however, the delineation of the biochemical\n\nand cellular pathways that cause the pathology remains the\n\nmost intrigant question on these disorders (Futerman and\n\nvan Meer 2004). One explanation is that the lysosomal\n\nstability is compromised, leading to the release of hydro-\n\nlases and accumulated metabolites in the citosol. It is well\n\nknown that lysosomal destabilization can lead to apoptosis\n\nand necrosis.\n\nLysosomes are very susceptible to oxidative stress (for a\n\nreview, see Terman et al. 2006), reactive species damage\n\nthe lisosomes endangering their permeability. Free radicals\n\nand other reactive species are involved in human diseases,\n\nbeing related in over 100 of them (Halliwell and Gutteridge\n\n1999), and these reactive molecules are formed during\n\nnormal aerobic metabolism in cells; however, uncontrolled\n\nproduction of free radicals results in damage to biomole-\n\ncules, leading to altered function and disease (Evans and\n\nHalliwell 1999). In LSD this imbalance might be even\n\nmore important due to the lysosomal overload. Despite\n\nmany studies relating oxidative damage to several disor-\n\nders, researches in LSD, especially MPS, lag seriously\n\nbehind. This mouse model of MPS I was generated by\n\nNeufeld and colleagues through disruption of the Idua gene\n\nby insertion in exon 6 of the neomycin resistance gene in\n\nthe opposite orientation. Through repeated back-crossing,\n\nthe mutant gene was inserted on C57BL/6 inbred back-\n\nground (Ohmi et al. 2003). We have previously described a\n\nspecific impairment of aversively motivated memory on\n\nthese mice (Reolon et al. 2006); this memory task could be\n\nused to evaluate the potential protective effect of experi-\n\nmental therapeutic approaches against cognitive deficits in\n\nmouse models of MPS I. The aim of this study was to\n\nevaluate oxidative stress biomarkers in the mice model of\n\nMPS I. To our knowledge, this is the first study evaluating\n\noxidative biomarkers in MPS I mice.\n\nMethods\n\nAnimals\n\nFive adult male C57BL/6 knockout mice for the Idua gene\n\n(Idua-/-) with 192 to 221 days of age were used as\n\nexperimental subjects. Five adult male C57BL/6 homozy-\n\ngous and heterozygous mice for the Idua gene with 192 to\n\n221 days of age were used as controls. Heterozygotes are\n\nasymptomatic and are commonly used as controls. Idua\n-/-\n\nmice were produced by target disruption of the murine Idua\n\ngene (Ohmi et al. 2003). The heterozygote animals pre-\n\ncursors of the colony were kindly provided by Dr.\n\nElizabeth Neufeld (University of California, Los Angeles,\n\nCA, USA). Homozygous mutants were identified on the\n\n21st day of life by polymerase chain reaction. Animals\n\nwere maintained on a 12-h light/dark cycle with food and\n\nwater available ad libitum. Brothers and sisters were bred\n\nand the colony was maintained by mating heterozygotes.\n\nAnimals were sacrificed by decapitation, and organs were\n\nquickly removed and stored for later analyses. The total\n\nlack of IDUA activity makes the knockout mice a MPS I\n\nHurler model.\n\nAll experimental procedures were in accordance with\n\nthe NIH Guide for Care and Use of Laboratory Animals\n\n(NIH publication No. 85-2 3 revised 1996) and the pro-\n\ncedures of the Brazilian College of Laboratory Animals\n\nand were approved by the institutional research ethics and\n\nanimal care committee.\n\nSuperoxide Dismutase Activity\n\nSuperoxide dismutase (SOD) activity was assayed by\n\nmeasuring the inhibition of adrenaline auto-oxidation, as\n\npreviously described (Bannister and Calabrese 1987).\n\nCatalase Activity\n\nCatalase (CAT) activity was assayed by measuring the rate\n\nof decrease of H2O2 absorbance at 240 nm (Aebi 1984).\n\nGlutathione Peroxidase Activity\n\nMeasuring glutathione peroxidase (GPx) activity was\n\nassayed measuring nicotinamide adenine dinucleotide\n\nphosphate diaphorase (NADPH) oxidation at 340 nm in the\n\n444 Cell Mol Neurobiol (2009) 29:443\u2013448\n\n123\n\n\n\npresence of reduced glutathione, tert-Butyl hydroperoxide,\n\nand glutathione reductase (Flohe? and Gu?nzler 1984).\n\nProtein Damage\n\nThe oxidative damage to proteins was assessed by the\n\ndetermination of carbonyl groups based on the reaction with\n\ndinitrophenylhydrazine (DNPH), as previously described\n\n(Levine et al. 1990). Briefly, proteins were precipitated by\n\nthe addition of 20% trichloroacetic acid (TCA) and redis-\n\nsolved in DNPH and the absorbance read at 370 nm.\n\nLipid Peroxidation\n\nAs an index of lipid peroxidation, the formation of thio-\n\nbarbituric acid-reactive substances (TBARS) during an\n\nacid-heating reaction has been used (Draper and Hadley\n\n1990). Briefly, the samples were mixed with 1 ml of TCA\n\n10% and 1 ml of thiobarbituric acid 0.67%, then heated in\n\na boiling water bath for 15 min. TBARS were determined\n\nby the absorbance at 535 nm. All the results were nor-\n\nmalized by the protein content (Lowry et al. 1951).\n\nStatistical Analysis\n\nAll data were presented as means \u00b1 standard error of the\n\nmean (SEM). Comparisons between control and MPS mice\n\nwere performed with independent samples Student t-tests.\n\nDifferences between the groups were rated significant at\n\nP \\ 0.05.\n\nResults\n\nSOD is considered a key antioxidant defense, dismutating\n\nsuperoxide anion-free radical into hydrogen peroxide, thus\n\nprotecting the cells from its damage. Results for SOD\n\nactivity are shown in Fig. 1. There were no statistically\n\nsignificant differences between knockout and control mice\n\nin the forebrain, heart and spleen. Knockout mice showed\n\nincreased SODs activity in the lung, liver and kidney\n\n(P \\ 0.05), cerebellum and diaphragm (P \\ 0.01).\nHydrogen peroxide also represents a risk for cells, two\n\nenzymatic defenses convert it into water and ground state\n\noxygen, catalase and GPx. Results for catalase activity are\n\nshown in Fig. 2. No statistically significant differences\n\nwere found between knockout and control mice in the\n\nforebrain, heart, diaphragm, liver and kidney. Knockout\n\nmice showed increased catalase activity in the cerebellum,\n\nspleen (P \\ 0.05), and in the lung (P \\ 0.01). There was\nno significant difference between knockout and control\n\nmice in GPx activity in any of the analyzed organs (data\n\nnot shown).\n\nThe carbonyl assay measures the formation of carbonyl\n\ngroups on proteins, these groups being formed after reac-\n\ntive species attacked the protein backbone. Results for\n\ncarbonyl assay are shown in Fig. 3. No statistically sig-\n\nnificant differences were found between knockout and\n\ncontrol mice in the forebrain, lung, diaphragm, liver and\n\nkidney. Knockout mice showed a high increase on carbonyl\n\ngroups in the cerebellum, heart and spleen (P \\ 0.01).\nTBARS assay measures the formation of malondialde-\n\nhydes (MDA), which are products of lipid peroxidation.\n\nResults for TBARS assay are shown in Fig. 4. There was\n\nno significant difference between knockout and control\n\nmice in the forebrain, heart, lung, diaphragm, liver, kidney\n\nand spleen. Knockout mice showed a decrease of thiobar-\n\nbituric acid-reactive substances in the cerebellum\n\n(P \\ 0.05).\n\nDiscussion\n\nConsiderable evidence points toward the participation of\n\nreactive oxygen species (ROS), reactive nitrogen species\n\n(RNS) and free radicals in human diseases. Disturbing cell\n\nhomeostasis produces oxidative stress through several\n\nmechanisms (Halliwell and Gutteridge 1999). The intra-\n\nlysosomal GAGs accumulation, directly or not, may have\n\nan influence on oxidative imbalance. Cells exposed to\n\noxidative stress enhance the antioxidant defenses in an\n\nattempt to reestablish homeostasis. Our results showed an\n\nincrease on SOD activity in the cerebellum, lung, dia-\n\nphragm, liver and kidney; CAT activity was increased on\n\nthe cerebellum, lung and spleen. We found abnormal\n\ndamage to proteins on the heart, spleen and cerebellum.\n\nThe TBARS level was decreased on the cerebellum. It is\n\npossible that the enzymatic defense is unable to prevent the\n\nprotein damage through enhanced production of reactive\n\nspecies on the heart, spleen and cerebellum while this\n\ncompensation could be occurring on the other tissues. The\n\ncerebellum, where two enzymatic defenses were enhanced,\n\ncould not prevent protein damage; however, it diminished\n\nbasal lipid damage.\n\nIn different neurodegenerations, an inflammatory pro-\n\ncess on the central nervous system is believed to be\n\ninvolved in the neuronal death. Pathological activation of\n\nmicroglia might trigger the release of neurotoxic sub-\n\nstances, such as ROS and RNS. On LSD, microglia have\n\nalso been suggested as having an involvement in the\n\npathology of MPS I and MPS IIIB (Ohmi et al. 2003), GM1\n\ngangliosidosis (Jeyakumar et al. 2003), metachromatic\n\nleukodistrophy (Hess et al. 1996), Niemann-Pieck type C\n\n(German et al. 2002) and krabe disease (Wu et al. 2000).\n\nCell Mol Neurobiol (2009) 29:443\u2013448 445\n\n123\n\n\n\nOn GM1 gangliosidosis (Jeyakumar et al. 2003), a footprint\n\nof nitric oxide was found on macrophages, an indication\n\nthat these cells could be causing oxidative damage. The\n\nauthors suggest that microglial activation enhances damage\n\nthrough inflammation and/or through ROS/RNS released.\n\nThere was a ninefold increase in MDA levels, and a\n\ndiminished glutathione (GSH, an important antioxidant) on\n\nthe brain of Sandhoff mice (Jeyakumar et al. 2004). The\n\nuse of anti-inflammatory and antioxidant drugs delays loss\n\nof motor coordination and ameliorate other parameters in\n\nFig. 1 Superoxide dismutase\nactivity in different organs of\n\nnormal and knockout mice.\n\nData are expressed as\n\nmean \u00b1 SEM. n = 5 animals\nper group. * P \\ 0.05,\n** P \\ 0.01 compared to the\ncontrol group\n\nFig. 2 Catalase activity on\ndifferent organs of normal and\n\nknockout mice. Data are\n\nexpressed as mean \u00b1 SEM.\n\nn = 5 animals per group.\n* P \\ 0.05, ** P \\ 0.01\ncompared to the control group\n\nFig. 3 Protein carbonyl\nconcentration on different\n\norgans of normal and knockout\n\nmice. Data are expressed as\n\nmean \u00b1 SEM. n = 5 animals\nper group. ** P \\ 0.01\ncompared to control group\n\n446 Cell Mol Neurobiol (2009) 29:443\u2013448\n\n123\n\n\n\nthe mouse model of Sandhoff (Jeyakumar et al. 2004) and\n\nNiemann-Pick C diseases (Bascun?an-Castillo et al. 2004).\n\nMPS I and MPS IIIB mice models have been shown to\n\nhave activated microglia with large storage vacuoles on the\n\nforebrain (Ohmi et al. 2003). Both diseases showed\n\nincreased microglia gene expression of cytochrome b558\n\nthat is part of the NADPH oxidase complex, which is\n\nresponsible for the oxidative burst of phagocytes (Klegeris\n\nand McGeer 1994). In MPS IIIB mice, an increased\n\nexpression of components of the phagocyte NADPH oxi-\n\ndase was observed in the brain and cerebellum (Villani\n\net al. 2007).\n\nMPS I patients showed increased blood CAT activity\n\nand a transient decrease in SOD activity after enzyme\n\nreplacement therapy. TBARS and GSH levels were\n\nincreased when compared to reference levels (Pereira et al.\n\n2008). The authors suggest that as erythrocytes can absorb\n\nhydrogen peroxide from other cells (Halliwell and Gut-\n\nteridge 1999) the alterations observed might be caused by\n\nincreased production of hydrogen peroxide from different\n\ntissues.\n\nOur results showed no alteration on any parameter on\n\nthe forebrain. At first look this might seem in discordance\n\nwith a previous work that showed activated microglia on\n\nthe forebrain of MPS I mice (Ohmi et al. 2003). However,\n\nas a neurodegenerative disease, time is a crucial factor on a\n\ncross-sectional study. We analyzed 6\u20137 months males.\n\nOhmi et al. (2003) observed that the number of activated\n\nmicroglia cells increased at 6 months and evolved with\n\ntime, being more significant at 9 months. Thus, analyses of\n\nolder mice will probably show forebrain alteration. Studies\n\nof different time sections will reveal the progression of this\n\ndamage. It is important to acknowledge that there are dif-\n\nferent oxidative stress biomarkers, not used on this work.\n\nOur results show no alteration on the forebrain, but that\n\ndoes not exclude the possibility that there is a damage\n\noccurring which could be shown if other parameters were\n\nmeasured.\n\nThe heart, spleen and cerebellum presented a high for-\n\nmation of carbonyl groups. It is known that this can cause\n\nan autoimmune response through misidentification of those\n\ndamaged proteins as exogenous ones (Halliwell and Gut-\n\nteridge 1999), which in turn might trigger and/or enhance\n\ninflammation.\n\nA special attention should be given to the cerebellum. It\n\nwas altered on every biomarker (except for GPx). Russell\n\net al. (1998) observed a progressive loss of Purkinje cells\n\non the cerebellum of a similar Idua\n-/-\n\nmice model, starting\n\nat 4\u20135 months and increasing with time. The intralysoso-\n\nmal accumulation could be damaging Purkinje cells and\n\nother cells on cerebellum through lysosomal labilization\n\nand/or oxidative stress. This oxidative imbalance can work\n\nas a damage enhancer. It is not known if Purkinje cells die\n\nthrough apoptosis or necrosis; if it is due to the former,\n\nthen more oxidative imbalance could be occurring. It is\n\npossible that this loss of neurons activated microglia\n\nthrough phagocytosis and therefore triggered inflammation\n\nwith posterior oxidative damage. The protein damage could\n\nenhance even more this pathological inflammation. In the\n\nSandhoff model (Jeyakumar et al. 2003), the inflammation\n\nis place specific, which might be the same for MPS I,\n\noccurring on the cerebellum without affecting the fore-\n\nbrain. Or, another possibility is an influence on the onset of\n\nforebrain damage. It is possible that the intralysosomal\n\naccumulation is leading to an intrincated positive feedback\n\ndamage mechanism. It is noteworthy to say that, to our\n\nknowledge, no studies evaluating inflammation with\n\nmicroglia involvement on the cerebellum of MPS I have\n\nbeen done.\n\nIn summary, in the present study, we evaluate for the\n\nfirst time the alterations in oxidative biomarkers in differ-\n\nent tissues in a mouse MPS model. Further experiments\n\nshould examine the time course of the alterations in oxi-\n\ndative stress across different time intervals and the possible\n\nreversal of the alterations by enzyme replacement. The\n\nfindings suggest the possibility that antioxidants might be\n\nFig. 4 Malondialdehyde\n(MDA) concentration on\n\ndifferent organs of normal and\n\nknockout mice. Data are\n\nexpressed as mean \u00b1 SEM.\n\nn = 5 animals per group.\n* P \\ 0.05 compared to control\ngroup\n\nCell Mol Neurobiol (2009) 29:443\u2013448 447\n\n123\n\n\n\nuseful as adjuvant therapies to ameliorate or delay the\n\nsymptoms of MPS. Future studies analyzing the effect of\n\nexperimental therapies on oxidative biomarkers may help\n\nto elucidate an important question: Whether oxidative\n\nstress has a significant influence on MPS I or is a response\n\nto the primary disease processes without influencing the\n\ndisorder progression? Our results indicate that, at least,\n\nsome attention to this matter should be given.\n\nAcknowledgments This research was supported by the Millennium\nInstitute of Gene Therapy (CNPq-MCT grant 420036/2005-9), and\n\ngrants and fellowships from FAPERGS-RS and CAPES. The authors\n\nthank Dr. Elizabeth F. Neufeld for her generous gift of Idua?/- mice.\n\nReferences\n\nAebi H (1984) Catalase in vitro. Methods Enzymol 105:121\u2013126.\n\ndoi:10.1016/S0076-6879(84)05016-3\n\nBannister JV, Calabrese L (1987) Assays for SOD. Methods Biochem\n\nAnal 32:279\u2013312. doi:10.1002/9780470110539.ch5\n\nBascun?an-Castillo EC, Erickson RP, Howison CM, Hunter RJ,\n\nHeidenreich RH, Hicks C, Trouard TP, Gillies RJ (2004)\n\nTamoxifen and vitamin E treatments delay symptoms in the\n\nmouse model of Niemann-Pick C. J Appl Genet 45:461\u2013467\n\nDraper HH, Hadley M (1990) Malondialdehyde determination as\n\nindex of lipid peroxidation. Methods Enzymol 186:421\u2013431.\n\ndoi:10.1016/0076-6879(90)86135-I\n\nEvans P, Halliwell B (1999) Free radicals and hearing: cause,\n\nconsequence, and criteria. Ann NY Acad Sci 884:19\u201340. doi:\n\n10.1111/j.1749-6632.1999.tb08633.x\n\nFlohe? L, Gu?nzler WA (1984) Assays of glutathione peroxidase.\n\nMethods Enzymol 105:114\u2013121. doi:10.1016/S0076-6879(84)\n\n05015-1\n\nFuterman AH, van Meer G (2004) The cell biology of lysosomal\n\nstorage disorders. Nat Rev Mol Cell Biol 5:554\u2013565. doi:10.1038/\n\nnrm1423\n\nGerman DC, Liang CL, Song T, Yazdani U, Xie C, Dietschy JM\n\n(2002) Neurodegeneration in the Niemann-Pick C mouse: glial\n\ninvolvement. Neuroscience 109:437\u2013450. doi:10.1016/S0306-\n\n4522(01)00517-6\n\nHalliwell B, Gutteridge JMC (1999) Free radicals in biology and\n\nmedicine. Clarendon Press, Oxford\n\nHess B, Saftig P, Hartmann D, Coenen R, Lu?llmann-Rauch R, Goebel\n\nHH, Evers M, von Figura K, D\u2019Hooge R, Nagels G, De Deyn P,\n\nPeters C, Gieselmann V (1996) Phenotype of arylsulfatase A-\n\ndeficient mice: relationship to human metachromatic leukodys-\n\ntrophy. Proc Natl Acad Sci USA 93:14821\u201314826. doi:10.1073/\n\npnas.93.25.14821\n\nJeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel\n\nAC, d\u2019Azzo A, Perry VH, Butters TD, Dwek RA, Platt FM\n\n(2003) Central nervous system inflammation is a hallmark of\n\npathogenesis in mouse models of GM1 and GM2 gangliosidosis.\n\nBrain 126:974\u2013987. doi:10.1093/brain/awg089\n\nJeyakumar M, Smith DA, Williams IM, Borja MC, Neville DC,\n\nButters TD, Dwek RA, Platt FM (2004) NSAIDs increase\n\nsurvival in the Sandhoff disease mouse: synergy with N-\n\nbutyldeoxynojirimycin. Ann Neurol 56:642\u2013649. doi:10.1002/\n\nana.20242\n\nKlegeris A, McGeer PL (1994) Rat brain microglia and peritoneal\n\nmacrophages show similar responses to respiratory burst stim-\n\nulants. J Neuroimmunol 53:83\u201390. doi:10.1016/0165-5728(94)\n\n90067-1\n\nLevine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG,\n\nAhn BW, Shaltiel S, Stadtman ER (1990) Determination of\n\ncarbonyl content in oxidatively modified proteins. Methods\n\nEnzymol 186:464\u2013478. doi:10.1016/0076-6879(90)86141-H\n\nLowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein\n\nmeasurement with the Folin phenol reagent. J Biol Chem 193:\n\n265\u2013275\n\nNeufeld EF, Muenzer J (1995) The mucopolysaccharidoses. In:\n\nScriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic\n\nbasis of inherited diseases. McGraw-Hill, New York\n\nOhmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld\n\nEF (2003) Activated microglia in cortex of mouse models of\n\nmucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA\n\n100:1902\u20131907. doi:10.1073/pnas.252784899\n\nPereira VG, Martins AM, Micheletti C, D\u2019Almeida V (2008)\n\nMutational and oxidative stress analysis in patients with\n\nmucopolysaccharidosis type I undergoing enzyme replacement\n\ntherapy. Clin Chim Acta 387:75\u201379. doi:10.1016/j.cca.2007.09.\n\n008\n\nReolon GK, Braga LM, Camassola M, Luft T, Henriques JA, Nardi\n\nNB, Roesler R (2006) Long-term memory for aversive training is\n\nimpaired in Idua(-/-) mice, a genetic model of mucopolysaccha-\n\nridosis type I. Brain Res 1076:225\u2013230. doi:10.1016/j.brainres.\n\n2006.01.008\n\nRussell C, Hendson G, Jevon G, Matlock T, Yu J, Aklujkar M, Ng\n\nKY, Clarke LA (1998) Murine MPS I: insights into the\n\npathogenesis of Hurler syndrome. Clin Genet 53:349\u2013361\n\nTerman A, Kurz T, Gustafsson B, Brunk UT (2006) Lysosomal\n\nlabilization. IUBMB Life 58:531\u2013539. doi:10.1080/1521654\n\n0600904885\n\nVillani GR, Gargiulo N, Faraonio R, Castaldo S, Gonzalez Y, Reyero E,\n\nDi Natale P (2007) Cytokines, neurotrophins, and oxidative stress\n\nin brain disease from mucopolysaccharidosis IIIB. J Neurosci Res\n\n85:612\u2013622. doi:10.1002/jnr.21134\n\nWu YP, Matsuda J, Kubota A, Suzuki K, Suzuki K (2000) Infiltration\n\nof hematogenous lineage cells into the demyelinating central\n\nnervous system of twitcher mice. J Neuropathol Exp Neurol\n\n59:628\u2013639\n\n448 Cell Mol Neurobiol (2009) 29:443\u2013448\n\n123\n\nhttp://dx.doi.org/10.1016/S0076-6879(84)05016-3\nhttp://dx.doi.org/10.1002/9780470110539.ch5\nhttp://dx.doi.org/10.1016/0076-6879(90)86135-I\nhttp://dx.doi.org/10.1111/j.1749-6632.1999.tb08633.x\nhttp://dx.doi.org/10.1016/S0076-6879(84)05015-1\nhttp://dx.doi.org/10.1016/S0076-6879(84)05015-1\nhttp://dx.doi.org/10.1038/nrm1423\nhttp://dx.doi.org/10.1038/nrm1423\nhttp://dx.doi.org/10.1016/S0306-4522(01)00517-6\nhttp://dx.doi.org/10.1016/S0306-4522(01)00517-6\nhttp://dx.doi.org/10.1073/pnas.93.25.14821\nhttp://dx.doi.org/10.1073/pnas.93.25.14821\nhttp://dx.doi.org/10.1093/brain/awg089\nhttp://dx.doi.org/10.1002/ana.20242\nhttp://dx.doi.org/10.1002/ana.20242\nhttp://dx.doi.org/10.1016/0165-5728(94)90067-1\nhttp://dx.doi.org/10.1016/0165-5728(94)90067-1\nhttp://dx.doi.org/10.1016/0076-6879(90)86141-H\nhttp://dx.doi.org/10.1073/pnas.252784899\nhttp://dx.doi.org/10.1016/j.cca.2007.09.008\nhttp://dx.doi.org/10.1016/j.cca.2007.09.008\nhttp://dx.doi.org/10.1016/j.brainres.2006.01.008\nhttp://dx.doi.org/10.1016/j.brainres.2006.01.008\nhttp://dx.doi.org/10.1080/15216540600904885\nhttp://dx.doi.org/10.1080/15216540600904885\nhttp://dx.doi.org/10.1002/jnr.21134\n\n\n33 \n\n \n\nDISCUSS\u00c3O \n\n \n\n A utiliza\u00e7\u00e3o de modelos animais de MPS I possibilita avaliar a efic\u00e1cia de \n\ndiferentes terapias (CLARKE et al., 1997; OHMI et al., 2003). Os par\u00e2metros \n\nutilizados na avalia\u00e7\u00e3o terap\u00eautica na MPS I s\u00e3o: o ac\u00famulo lisossomal, a \n\natividade da ?-L-iduronidase, a concentra\u00e7\u00e3o dos GAGs excretados pela urina e \n\nas anormalidades esquel\u00e9ticas. \n\n No SNC, esses par\u00e2metros s\u00e3o: o ac\u00famulo lisossomal, o ac\u00famulo de GM2 e \n\nGM3 e a morte neuronal no cerebelo (RUSSELL et al., 1998; DESMARIS et al., \n\n2004; HARTUNG et al., 2004; CHUNG et al., 2007). Os crit\u00e9rios acima \n\nmencionados n\u00e3o avaliam a fun\u00e7\u00e3o cognitiva. Devido ao comprometimento do \n\nSNC, \u00e9 necess\u00e1ria a caracteriza\u00e7\u00e3o de par\u00e2metros de d\u00e9ficit cognitivo que \n\npossam ser utilizados na avalia\u00e7\u00e3o terap\u00eautica. At\u00e9 o momento, somente \n\nHARTUNG et al. (2004) avaliaram a mem\u00f3ria de habitua\u00e7\u00e3o no campo aberto de \n\num modelo de MPS I. \n\n Nosso trabalho utilizou dois paradigmas de aprendizado, a esquiva inibit\u00f3ria \n\ne o reconhecimento de objeto. A esquiva inibit\u00f3ria \u00e9 um modelo amplamente \n\nutilizado de mem\u00f3ria aversiva (IZQUIERDO &amp; MEDINA, 1997; MCGAUGH, 2000). \n\nO reconhecimento de objeto avalia a mem\u00f3ria n\u00e3o aversiva, sendo um teste \u00fatil \n\nna avalia\u00e7\u00e3o de mudan\u00e7as no SNC de modelos gen\u00e9ticos (TANG et al., 1999; \n\nRAMPON et al., 2000). Tamb\u00e9m avaliamos o comportamento no campo aberto e \n\na resposta dos animais ao choque do aparelho de esquiva inibit\u00f3ria. \n\n\n\n34 \n\n \n\n Os resultados da esquiva inibit\u00f3ria n\u00e3o demostraram diferen\u00e7a significativa \n\nentre os grupos no treino ou na mem\u00f3ria de curta dura\u00e7\u00e3o. Contudo, a mem\u00f3ria \n\nde longa dura\u00e7\u00e3o estava prejudicada nos animais knockout. No teste de \n\nreconhecimento de objeto, n\u00e3o houve diferen\u00e7a entre os grupos no treino, na \n\nmem\u00f3ria de curta e de longa dura\u00e7\u00e3o. No comportamento de campo aberto, n\u00e3o \n\nexistiu diferen\u00e7a significativa entre os grupos na lat\u00eancia, no n\u00famero de crossings \n\ne no n\u00famero de bolos fecais. Houve uma redu\u00e7\u00e3o no n\u00famero de rearings nos \n\nanimais knockout. A reatividade ao choque n\u00e3o se mostrou alterada nesses \n\nanimais, n\u00e3o havendo diferen\u00e7a significativa entre os grupos no flinch e no jump. \n\n O principal achado deste trabalho \u00e9 o d\u00e9ficit apresentado pelos \n\ncamundongos Idua \n-/- \n\nna mem\u00f3ria de longa dura\u00e7\u00e3o de esquiva inibit\u00f3ria. Todavia, \n\na mem\u00f3ria de curta dura\u00e7\u00e3o n\u00e3o estava afetada. \n\n A forma\u00e7\u00e3o de mem\u00f3rias aversivas de longa dura\u00e7\u00e3o \u00e9 modulada pela \n\nlibera\u00e7\u00e3o de horm\u00f4nios e neurotransmissores associados \u00e0 exposi\u00e7\u00e3o a eventos \n\nemocionais. A am\u00edgdala basolateral \u00e9 cr\u00edtica na consolida\u00e7\u00e3o da mem\u00f3ria \n\naversiva de longa dura\u00e7\u00e3o (MCGAUGH, 2000). \u00c9 poss\u00edvel que a diferen\u00e7a \n\nobservada nos animais seja devido a altera\u00e7\u00f5es na libera\u00e7\u00e3o de horm\u00f4nios \n\nassociados a eventos estressantes e/ou mudan\u00e7as na funcionalidade normal da \n\nam\u00edgdala. At\u00e9 o momento, n\u00e3o foram realizados estudos sobre os horm\u00f4nios \n\nassociados a eventos estressantes ou \u00e0 fun\u00e7\u00e3o da am\u00edgdala na MPS I. \n\n As mem\u00f3rias de curta e de longa dura\u00e7\u00e3o de esquiva inibit\u00f3ria necessitam \n\nda integridade do hipocampo dorsal, mas possuem diferentes mecanismos \n\nneuroqu\u00edmicos (IZQUIERDO &amp; MEDINA, 1997; MCGAUGH, 2000; ROESLER et \n\nal., 2003; QUEVEDO et al., 2004). O d\u00e9ficit na esquiva inibit\u00f3ria pode ser devido \u00e0 \n\n\n\n35 \n\n \n\naltera\u00e7\u00e3o na funcionalidade normal do hipocampo. No modelo murino da MPS I, j\u00e1 \n\nfoi demonstrado o ac\u00famulo patol\u00f3gico dos GAGs em neur\u00f4nios hipocampais \n\n(DESMARIS et al., 2004; HARTUNG et al., 2004). No modelo da Leucodistrofia \n\nMetacrom\u00e1tica (outra LSD) ocorre degenera\u00e7\u00e3o seletiva de neur\u00f4nios piramidais \n\ndo hipocampo dorsal (CONSIGLIO et al., 2001). \n\n Nos animais knockout, o teste de reconhecimento de objeto n\u00e3o se mostrou \n\nalterado. A mem\u00f3ria desse teste \u00e9 declarativa n\u00e3o aversiva, diferindo da esquiva \n\ninibit\u00f3ria, cuja mem\u00f3ria \u00e9 n\u00e3o declarativa e aversiva. As diferen\u00e7as entre as duas \n\nmem\u00f3rias podem explicar os resultados distintos observados. HARTUNG et al. \n\n(2004) encontraram d\u00e9ficit de mem\u00f3ria n\u00e3o aversiva e n\u00e3o associativa, o que \n\ncontrasta com os nossos resultados, que indicaram d\u00e9ficit na mem\u00f3ria aversiva, \n\nmas n\u00e3o na mem\u00f3ria n\u00e3o aversiva de camundongos Idua \n-/-\n\n. A diferen\u00e7a entre os \n\nachados pode ser decorrente do tipo de teste utilizado. \n\n Em modelos animais com dano cerebral, o teste de par\u00e2metros \n\ncomportamentais precisa excluir a influ\u00eancia de disfun\u00e7\u00f5es no Sistema Sensorial \n\nou Locomotor, pois os achados poderiam ser erroneamente interpretados como \n\naltera\u00e7\u00f5es cognitivas. Os pacientes portadores da s\u00edndrome de Hurler apresentam \n\naltera\u00e7\u00f5es importantes no Sistema Sensorial e Locomotor (NEUFELD &amp; \n\nMUENZER, 2001) e o modelo murino reproduz adequadamente o amplo espectro \n\nde altera\u00e7\u00f5es observadas nos pacientes (RUSSELL et al., 1998). \n\n Avaliamos animais com a idade m\u00e9dia de 25 semanas e nossos resultados \n\nindicam que, nessa idade, as altera\u00e7\u00f5es esquel\u00e9ticas ainda n\u00e3o incapacitam a \n\nlocomo\u00e7\u00e3o. Considerando os problemas articulares e esquel\u00e9ticos que os \n\npacientes portadores da s\u00edndrome de Hurler e os camundongos apresentam, essa \n\n\n\n36 \n\n \n\n\u00e9 uma quest\u00e3o relevante a ser observada. No campo aberto, os animais testados \n\nmostraram a mesma locomo\u00e7\u00e3o do grupo controle. Esses animais apresentam \n\nanormalidades esquel\u00e9ticas que iniciam \u00e0s quatro semanas de idade; com oito \n\nsemanas, ocorrem altera\u00e7\u00f5es nas patas. Na idade de 40 semanas, os animais \n\nn\u00e3o s\u00e3o mais capazes de se movimentarem. O quadro cl\u00ednico caracter\u00edstico das \n\nLSD, a disostose m\u00faltipla, s\u00f3 \u00e9 completamente evidenciado na 57\u00aa semana de \n\nvida. \n\n As articula\u00e7\u00f5es dos pacientes com MPS I-Hurler s\u00e3o gravemente afetadas, \n\nimpossibilitando a realiza\u00e7\u00e3o de diversos movimentos. No modelo animal, n\u00e3o \n\nforam avaliadas as altera\u00e7\u00f5es articulares. A redu\u00e7\u00e3o do comportamento \n\nexplorat\u00f3rio observado no campo aberto pode ser devida \u00e0 incapacidade do \n\nanimal de erguer-se e/ou se manter sobre as duas patas. Dessa forma, essa \n\naltera\u00e7\u00e3o necessita de estudos posteriores visando determinar sua causalidade. \n\n Na s\u00edndrome de Hurler, os pacientes apresentam altera\u00e7\u00f5es importantes no \n\nSistema Sensorial. Os animais aprenderam normalmente a tarefa de esquiva \n\ninibit\u00f3ria e a tarefa de reconhecimento de objeto que envolvem diferentes sentidos \n\npara o aprendizado. Esses dados indicam que, na idade m\u00e9dia de 25 semanas, a \n\nfuncionalidade do Sistema Sensorial capacita os animais a aprenderem os testes \n\nde reconhecimento de objeto e de esquiva inibit\u00f3ria. \n\n O d\u00e9ficit observado na mem\u00f3ria de longa dura\u00e7\u00e3o de esquiva inibit\u00f3ria \n\npoderia ser devido a altera\u00e7\u00f5es no Sistema Nociceptivo. Para excluir a \n\ninterfer\u00eancia de poss\u00edveis altera\u00e7\u00f5es nociceptivas, avaliamos a resposta ao \n\nchoque, tendo os animais knockout e o grupo controle apresentado a mesma \n\nresposta. \n\n\n\n37 \n\n \n\n Ap\u00f3s o controle das vari\u00e1veis relacionadas a fatores sensoriais e/ou \n\nlocomotores, podemos afirmar que o d\u00e9ficit observado na mem\u00f3ria de longa \n\ndura\u00e7\u00e3o de esquiva inibit\u00f3ria n\u00e3o foi causado por altera\u00e7\u00f5es nociceptivas e/ou \n\nsens\u00f3rio-motoras. Nossos resultados mostram um d\u00e9ficit espec\u00edfico na mem\u00f3ria \n\naversiva de longa dura\u00e7\u00e3o de esquiva inibit\u00f3ria. Os achados acima possibilitam ao \n\nteste de esquiva inibit\u00f3ria sua utiliza\u00e7\u00e3o na avalia\u00e7\u00e3o dos efeitos de diferentes \n\nabordagens terap\u00eauticas sobre os d\u00e9ficits cognitivos no modelo murino da MPS I-\n\nHurler. Estudos posteriores ser\u00e3o necess\u00e1rios para investigar as altera\u00e7\u00f5es \n\nrespons\u00e1veis pela disfun\u00e7\u00e3o da mem\u00f3ria. \n\n \u00c9 importante ressaltar que foram utilizados animais com a idade m\u00e9dia de 25 \n\nsemanas, idade na qual \u00e9 poss\u00edvel observar danos diversos que s\u00e3o par\u00e2metros \n\nutilizados na avalia\u00e7\u00e3o de diferentes terapias (RUSSELL et al., 1998). Entretanto, \n\no dano ao SNC, incluindo a morte celular cerebelar e a inflama\u00e7\u00e3o cerebral, \n\nocorre mais tardiamente nos animais knockout. O estudo de par\u00e2metros \n\ncognitivos em diferentes idades pode definir o in\u00edcio e a progress\u00e3o de diferentes \n\ndanos cognitivos. Provavelmente, animais mais velhos ter\u00e3o danos cognitivos \n\nmais graves do que os apresentados pelos camundongos do presente estudo. \n\n O estresse oxidativo \u00e9 o desequil\u00edbrio entre antioxidantes e pr\u00f3-\n\noxidantes. Em doen\u00e7as, isso geralmente ocorre pelo aumento na produ\u00e7\u00e3o de \n\nesp\u00e9cies reativas de oxig\u00eanio (EROs) e/ou esp\u00e9cies reativas de nitrog\u00eanio \n\n(ERNs). Existe uma forte rela\u00e7\u00e3o entre a inflama\u00e7\u00e3o no SNC e o desequil\u00edbrio \n\noxidativo, podendo o processo inflamat\u00f3rio levar ao estressse oxidativo \n\n(HALLIWELL &amp; GUTTERIDGE, 1999). Diferentes trabalhos encontraram \n\ninflama\u00e7\u00e3o com participa\u00e7\u00e3o da microglia no SNC dos pacientes portadores das \n\n\n\n38 \n\n \n\nLSD. J\u00e1 foi proposto que o ac\u00famulo de GAGs e/ou a morte neuronal ativariam \n\npatologicamente a microglia, levando \u00e0 libera\u00e7\u00e3o aumentada de EROs/ERNs. A \n\nmelhora observada em modelos animais de LSD tratados com antioxidantes \n\nindica uma poss\u00edvel influ\u00eancia do estresse oxidativo nessas patologias. \n\n C\u00e9lulas expostas ao estresse oxidativo aumentam suas defesas \n\nantioxidantes na tentativa de restabelecer o equil\u00edbrio. Nossos resultados \n\nmostraram um aumento das defesas antioxidantes dos animais knockout quando \n\ncomparadas ao grupo controle. O cerebelo, o pulm\u00e3o, o diafragma, o f\u00edgado e o \n\nrim apresentaram aumento na atividade da super\u00f3xido dismutase (SOD). A \n\natividade da catalase estava aumentada no cerebelo, no pulm\u00e3o e no ba\u00e7o. Este \n\nachado pode refletir a tentativa de restabelecimento da homeostase. Ao \n\nanalisarmos a forma\u00e7\u00e3o de grupos carbonil, biomarcador de dano a prote\u00ednas por \n\nradicais livres, verificou-se seu aumento no cerebelo, no cora\u00e7\u00e3o e no ba\u00e7o dos \n\ncamundongos knockout em rela\u00e7\u00e3o aos animais do grupo controle. N\u00e3o foram \n\nobservadas altera\u00e7\u00f5es das defesas antioxidantes no cora\u00e7\u00e3o. Dessa forma, \n\npoder-se-ia atribuir o dano observado ao aumento das esp\u00e9cies reativas. \u00c9 \n\nposs\u00edvel que, no cerebelo e no ba\u00e7o, o aumento verificado das defesas \n\nantioxidantes n\u00e3o consiga impedir o dano a prote\u00ednas, enquanto em outros \u00f3rg\u00e3os \n\nocorra essa compensa\u00e7\u00e3o. \n\n Nos camundongos knockout, o cerebelo, o cora\u00e7\u00e3o e o ba\u00e7o apresentam \n\nv\u00e1rias altera\u00e7\u00f5es (RUSSELL et al., 1998; JORDAN et al., 2005). Os canais de \n\npot\u00e1ssio s\u00e3o suscept\u00edveis ao ataque das EROs/ERNs. No SNC e no m\u00fasculo \n\ncard\u00edaco, os canais de pot\u00e1ssio desempenham papel importante, podendo influir \n\nna morte neuronal e na disfun\u00e7\u00e3o card\u00edaca. O ba\u00e7o apresenta grande infiltra\u00e7\u00e3o \n\n\n\n39 \n\n \n\nde macr\u00f3fagos, existindo a possibilidade dessas c\u00e9lulas exercerem influ\u00eancia \n\nsobre o dano proteico. \n\n O SNC \u00e9 altamente sens\u00edvel ao estresse oxidativo. Dentre as poss\u00edveis \n\ncausas da susceptibilidade cerebral ao estresse oxidativo, encontram-se o alto \n\nconsumo de oxig\u00eanio e a utiliza\u00e7\u00e3o de Ca\n+2\n\n. Al\u00e9m disso, muitos \n\nneurotransmissores s\u00e3o mol\u00e9culas auto-oxidantes, podendo reagir com oxig\u00eanio e \n\ngerar EROs. \n\n No cerebelo, a morte das c\u00e9lulas de Purkinje pode ocorrer devido \u00e0 necrose. \n\nA morte neuronal por necrose pode aumentar o estresse oxidativo das regi\u00f5es \n\ncircunjacentes atrav\u00e9s da libera\u00e7\u00e3o de \u00edons met\u00e1licos, pr\u00f3-oxidantes e enzimas \n\nlisossomais. Al\u00e9m disso, a morte neuronal, seja por necrose ou apoptose, pode \n\nativar a microglia atrav\u00e9s da fagocitose dos restos celulares desencadeando e/ou \n\naumentando o estresse oxidativo. \n\n A forma neuronal da enzima \u00f3xido n\u00edtrico sintetasa (nNOS) \u00e9 regulada \n\npositivamente por Ca\n+2\n\n / calmodulina. O desequil\u00edbrio na homeostase do Ca\n+2 \n\npresente em algumas LSD pode aumentar a libera\u00e7\u00e3o de \u00f3xido n\u00edtrico. No SNC, o \n\ncerebelo possui a mais alta concentra\u00e7\u00e3o de nNOS. Dessa forma, \u00e9 a regi\u00e3o \n\ncerebral mais suscept\u00edvel ao desequil\u00edbrio do Ca\n+2\n\n. Caso o desequil\u00edbrio do Ca\n+2 \n\nocorra tamb\u00e9m no modelo murino da MPS I, poderia ser uma explica\u00e7\u00e3o para os \n\nachados a n\u00edvel cerebelar. \n\n VILLANI et al. (2007) avaliaram a express\u00e3o g\u00eanica da nicotinamida adenina \n\ndinucleot\u00eddeo fosfato oxidase no telenc\u00e9falo e no cerebelo de camundongos MPS \n\nIIIB, tendo ambos apresentado aumento da sua express\u00e3o em cerca de 10 vezes. \n\n\n\n40 \n\n \n\nFoi o primeiro trabalho a estudar o processo inflamat\u00f3rio cerebelar nas MPS. \n\nEstudos anteriores sobre as altera\u00e7\u00f5es inflamat\u00f3rias das LSD enfocaram \n\nprincipalmente o telenc\u00e9falo, sem, contudo, avaliar as modifica\u00e7\u00f5es no cerebelo. \n\n As prote\u00ednas podem sofrer grande dano por radicais livres sem perda da sua \n\nfun\u00e7\u00e3o. Nas enzimas, a perda da fun\u00e7\u00e3o ocorre devido \u00e0 modifica\u00e7\u00e3o de um \n\namino\u00e1cido pertencente ou pr\u00f3ximo ao s\u00edtio ativo. O dano a prote\u00ednas pode \n\nprejudicar o funcionamento celular alterando receptores, enzimas e prote\u00ednas \n\nestruturais. As prote\u00ednas danificadas podem ser reconhecidas pelo Sistema \n\nImunol\u00f3gico como ex\u00f3genas, iniciando uma rea\u00e7\u00e3o autoimune.  Caso isso ocorra \n\nno modelo murino da MPS I, o estresse oxidativo poderia iniciar e/ou exacerbar a \n\nrea\u00e7\u00e3o inflamat\u00f3ria no cerebelo, cora\u00e7\u00e3o e ba\u00e7o. \n\n A peroxida\u00e7\u00e3o lip\u00eddica apresentou altera\u00e7\u00e3o somente no cerebelo, \n\ndiminuindo a forma\u00e7\u00e3o de dialde\u00eddo mal\u00f4nico (MDA). O SNC possui grande \n\nquantidade de \u00e1cidos graxos poli-insaturados (lip\u00eddios de maior suscetibilidade \u00e0 \n\nperoxida\u00e7\u00e3o lip\u00eddica), sendo esperado aumento na peroxida\u00e7\u00e3o lip\u00eddica e na \n\nforma\u00e7\u00e3o de MDA. Diferentes esp\u00e9cies reativas atacam preferencialmente \n\nalgumas biomol\u00e9culas. Indaga-se se o aumento observado na SOD e na catalase \n\npoderia prevenir e reduzir a peroxida\u00e7\u00e3o lip\u00eddica, embora n\u00e3o consiga evitar o \n\ndano a prote\u00ednas. \n\n Entre os mecanismos propostos de dano ao SNC na MPS I e em outras \n\nLSD, encontra-se o processo inflamat\u00f3rio com poss\u00edvel influ\u00eancia da micr\u00f3glia. \n\nTalvez o estresse oxidativo esteja tamb\u00e9m contribuindo para a progress\u00e3o da \n\ndoen\u00e7a. Existe a possibilidade de outras LSD apresentarem esse desequil\u00edbrio. \n\n\n\n41 \n\n \n\nExiste extensa literatura sobre a contribui\u00e7\u00e3o da inflama\u00e7\u00e3o cr\u00f4nica em doen\u00e7as \n\nneurodegenerativas, por\u00e9m, n\u00e3o h\u00e1 consenso sobre o papel da micr\u00f3glia. As \n\nmol\u00e9culas sintetizadas por essas c\u00e9lulas e o seu padr\u00e3o de express\u00e3o podem \n\nmudar ao longo da evolu\u00e7\u00e3o da doen\u00e7a (MINGHETTI, 2005). Considera-se a \n\npossibilidade do seu papel inicial ser ben\u00e9fico, fagocitando restos celulares e \n\nGAGs da matriz extracelular. Entretanto, a micr\u00f3glia apresenta modifica\u00e7\u00f5es com \n\na progress\u00e3o da patologia. A ativa\u00e7\u00e3o excessiva e o envelhecimento s\u00e3o dois \n\nfatores comprovados de ativa\u00e7\u00e3o patol\u00f3gica de fag\u00f3citos pass\u00edveis de \n\ndesencadear danos. \n\n Trabalhos sugerem que os GAGs possuam propriedades antioxidantes \n\n(PRESTI &amp; SCOTT, 1994; ALBERTINI et al., 1999; ARAI et al., 1999). Estudos in \n\nvitro com fibroblastos normais mostraram que heparan sulfato e dermatan sulfato \n\nt\u00eam pouca atividade antioxidante (CAMPO et al., 2004), protegendo as c\u00e9lulas do \n\ndano induzido por ferro e cobre. As implica\u00e7\u00f5es desses achados para a MPS I \n\nainda n\u00e3o foram estudadas. \n\n \u00c9 importante ressaltar o papel do dano tecidual como promotor do estresse \n\noxidativo. Desta forma, a causa prim\u00e1ria da patologia, o ac\u00famulo de GAGs, \n\npoderia ser a causa da altera\u00e7\u00e3o do equil\u00edbrio oxidativo. Em segundo lugar, \n\nindaga-se sobre a real influ\u00eancia do desequil\u00edbrio oxidativo no desenvolvimento da \n\npatologia. As c\u00e9lulas podem aumentar as defesas antioxidantes e, caso o \n\nestresse seja neutralizado, n\u00e3o ocorreria contribui\u00e7\u00e3o do desequil\u00edbrio oxidativo \n\npara a doen\u00e7a. Se o estresse ocorrer na fase final da doen\u00e7a, geralmente por \n\ndanos aos tecidos causados pela patologia, ela poderia n\u00e3o ter contribui\u00e7\u00e3o \n\nsignificativa ou poderia agravar ainda mais o dano. Caso o estresse oxidativo \n\n\n\n42 \n\n \n\nocorra no est\u00e1gio inicial da doen\u00e7a, sem defesas antioxidantes adequadas, \n\npoderia haver uma contribui\u00e7\u00e3o significativa para o desenvolvimento da patologia. \n\n \u00c9 importante ressaltar a exist\u00eancia de diferentes biomarcadores de estresse \n\noxidativo para tipos distintos de danos a biomol\u00e9culas. A utiliza\u00e7\u00e3o desses \n\nmarcadores n\u00e3o exclui a possibilidade de ocorr\u00eancia n\u00e3o detectada de outros \n\ndanos, o que poderia explicar a aus\u00eancia de dano ao telenc\u00e9falo. Estudos com \n\nmarcadores distintos poderiam contribuir para melhor entendimento da doen\u00e7a. \n\n\n\n43 \n\n \n\nREFER\u00caNCIAS BIBLIOGR\u00c1FICAS \n\n \n\n1. ALBERTINI R.; DE LUCA G.; PASSI A.; MORATTI R. &amp; ABUJA P. M. \nChondroitin-4-sulfate protects high-density lipoprotein against copper-dependent \noxidation. Arch Biochem Biophys, 365(1): 143-149, 1999. \n\n2. ARAI H.; KASHIWAGI S.; NAGASAKA Y.; UCHIDA K.; HOSHII Y. &amp; NAKAMURA \nK. Oxidative modification of apolipoprotein E in human very-low-density lipoprotein \nand its inhibition by glycosaminoglycans. Arch Biochem Biophys, 367(1): 1-8, \n1999. \n\n3. ARIKAWA-HIRASAWA E.; WILCOX W. R. &amp; YAMADA Y. Dyssegmental \ndysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage \ndevelopment. Am J Med Genet, 106(4): 254-257, 2001. \n\n4. ARIKAWA-HIRASAWA E. &amp; YAMADA Y. Roles of perlecan in development and \ndisease: studies in knockout mice and human disorders. Seikagaku, 73(10): 1257-\n1261, 2001. \n\n5. AULA P.; RAPPEL J. &amp; ANDERSSON C. Distribution of cytoplasmatic vacuoles \nin blood T and B lymphocytes in two lysosomal disorders. Virchows Arch B Cell \nPathol, 18(4): 263\u2013271, 1975. \n\n6. BAHR B. A. &amp; BENDISKE J. The neuropathogenic contributions of lysosomal \ndysfunction. J Neurochem, 83(3): 481-489, 2002. \n\n7. BASCUNAN-CASTILLO E. C.; ERICKSON R. P.; HOWISON C. M.; HUNTER R. \nJ.; HEIDENREICH R. H.; HICKS C.; TROUARD T. P. &amp; GILLIES R. J. Tamoxifen \nand vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C. \nJ Appl Genet, 45(4): 461-467, 2004. \n\n8. BAUDRY M.; YAO Y.; SIMMONS D.; LIU J. &amp; BI X. Postnatal development of \ninflammation in a murine model of Niemann-Pick type C disease: \nimmunohistochemical observations of microglia and astroglia. Exp Neurol, 184(2): \n887-903, 2003. \n\n9. BERNFIELD M.; GOTTE M.; PARK P. W.; REIZES O.; FITZGERALD M. L.; \nLINCECUM J. &amp; ZAKO M. Functions of cell surface heparan sulfate proteoglycans. \nAnnu Rev Biochem, 68: 729-777, 1999. \n\n10. BRUCK W.; GOEBEL H. H. &amp; DIENES P. B and T lymphocytes are affected in \nlysosomal disorders--an immunoelectron microscopic study. Neuropathol Appl \nNeurobiol, 17(3): 219-222, 1991. \n\n\n\n44 \n\n \n\n11. CAMPO G. M.; D'ASCOLA A.; AVENOSO A.; CAMPO S.; FERLAZZO A. M.; \nMICALI C.; ZANGHI L. &amp; CALATRONI A. Glycosaminoglycans reduce oxidative \ndamage induced by copper (Cu+2), iron (Fe+2) and hydrogen peroxide (H2O2) in \nhuman fibroblast cultures. Glycoconj J, 20(2): 133-141, 2004. \n\n12. CHUNG S.; MA X.; LIU Y.; LEE D.; TITTIGER M. &amp; PONDER K. P. Effect of \nneonatal administration of a retroviral vector expressing alpha-L-iduronidase upon \nlysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol \nGenet Metab, 90(2): 181-192, 2007. \n\n13. CLARKE L. A.; RUSSELL C. S.; POWNALL S.; WARRINGTON C. L.; \nBOROWSKI A.; DIMMICK J. E.; TOONE J. &amp; JIRIK F. R. Murine \nmucopolysaccharidosis type I: targeted disruption of the murine alpha-L-\niduronidase gene. Hum Mol Genet, 6(4): 503-511, 1997. \n\n14. CONSIGLIO A.; QUATTRINI A.; MARTINO S.; BENSADOUN J. C.; DOLCETTA \nD.; TROJANI A.; BENAGLIA G.; MARCHESINI S.; CESTARI V.; OLIVERIO A.; \nBORDIGNON C. &amp; NALDINI L. In vivo gene therapy of metachromatic \nleukodystrophy by lentiviral vectors: correction of neuropathology and protection \nagainst learning impairments in affected mice. Nat Med, 7(3): 310-316, 2001. \n\n15. CONSTANTOPOULOS G.; IQBAL K. &amp; DEKABAN A. S. \nMucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of \nisolated brain cells and other fractions from autopsied tissues. J Neurochem, \n34(6): 1399-1411, 1980. \n\n16. CONSTANTOPOULOS G.; SHULL R. M.; HASTINGS N. &amp; NEUFELD E. F. \nNeurochemical characterization of canine alpha-L-iduronidase deficiency disease \n(model of human mucopolysaccharidosis I). J Neurochem, 45(4): 1213-1217, \n1985. \n\n17. DEKABAN A. S. &amp; CONSTANTOPOULOS G. Mucopolysaccharidosis type I, II, \nIIIA and V. Pathological and biochemical abnormalities in the neural and \nmesenchymal elements of the brain. Acta Neuropathol, 39(1): 1-7, 1977. \n\n18. DESMARIS N.; VEROT L.; PUECH J. P.; CAILLAUD C.; VANIER M. T. &amp; \nHEARD J. M. Prevention of neuropathology in the mouse model of Hurler \nsyndrome. Ann Neurol, 56(1): 68-76, 2004. \n\n19. ESKELINEN E. L.; TANAKA Y. &amp; SAFTIG P. At the acidic edge: emerging \nfunctions for lysosomal membrane proteins. Trends Cell Biol, 13(3): 137-145, \n2003. \n\n20. FUTERMAN A. H. &amp; VAN MEER G. The cell biology of lysosomal storage \ndisorders. Nat Rev Mol Cell Biol, 5(7): 554-565, 2004. \n\n21. GINSBERG S. D.; GALVIN J. E.; LEE V. M.; RORKE L. B.; DICKSON D. W.; \nWOLFE J. H.; JONES M. Z. &amp; TROJANOWSKI J. Q. Accumulation of intracellular \n\n\n\n45 \n\n \n\namyloid-beta peptide (A beta 1-40) in mucopolysaccharidosis brains. J \nNeuropathol Exp Neurol, 58(8): 815-824, 1999. \n\n22. GROFFEN A. J.; VEERKAMP J. H.; MONNENS L. A. &amp; VAN DEN HEUVEL L. \nP. Recent insights into the structure and functions of heparan sulfate \nproteoglycans in the human glomerular basement membrane. Nephrol Dial \nTransplant, 14(9): 2119-2129, 1999. \n\n23. HALLIWELL B. &amp; GUTTERIDGE J. M. C. Free radicals in biology and medicine. \n3a ed., Oxford University Press, 1999. \n\n24. HARTUNG S. D.; FRANDSEN J. L.; PAN D.; KONIAR B. L.; GRAUPMAN P.; \nGUNTHER R.; LOW W. C.; WHITLEY C. B. &amp; MCIVOR R. S. Correction of \nmetabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth \nwith adeno-associated virus vector transducing the human alpha-L-iduronidase \ngene. Mol Ther, 9(6): 866-875, 2004. \n\n25. HOCH W. Formation of the neuromuscular junction. Agrin and its unusual \nreceptors. Eur J Biochem, 265(1): 1-10, 1999. \n\n26. IOZZO R. V. Heparan sulfate proteoglycans: intricate molecules with intriguing \nfunctions. J Clin Invest, 108(2): 165-167, 2001. \n\n27. IZQUIERDO I. &amp; MEDINA J. H. Memory formation: the sequence of \nbiochemical events in the hippocampus and its connection to activity in other brain \nstructures. Neurobiol Learn Mem, 68(3): 285-316, 1997. \n\n28. JEYAKUMAR M.; DWEK R. A.; BUTTERS T. D. &amp; PLATT F. M. Storage \nsolutions: treating lysosomal disorders of the brain. Nat Rev Neurosci, 6(9): 713-\n725, 2005. \n\n29. JEYAKUMAR M.; THOMAS R.; ELLIOT-SMITH E.; SMITH D. A.; VAN DER \nSPOEL A. C.; D'AZZO A.; PERRY V. H.; BUTTERS T. D.; DWEK R. A. &amp; PLATT F. \nM. Central nervous system inflammation is a hallmark of pathogenesis in mouse \nmodels of GM1 and GM2 gangliosidosis. Brain, 126(Pt 4): 974-987, 2003. \n\n30. JORDAN M. C.; ZHENG Y.; RYAZANTSEV S.; ROZENGURT N.; ROOS K. P. &amp; \nNEUFELD E. F. Cardiac manifestations in the mouse model of \nmucopolysaccharidosis I. Mol Genet Metab, 86(1-2): 233-243, 2005. \n\n31. JOURNET A.; CHAPEL A.; KIEFFER S.; ROUX F. &amp; GARIN J. Proteomic \nanalysis of human lysosomes: application to monocytic and breast cancer cells. \nProteomics, 2(8): 1026-1040, 2002. \n\n32. KIESEIER B. C.; WISNIEWSKI K. E. &amp; GOEBEL H. H. The monocyte-\nmacrophage system is affected in lysosomal storage diseases: an immunoelectron \nmicroscopic study. Acta Neuropathol, 94(4): 359-362, 1997. \n\n\n\n46 \n\n \n\n33. LAPLANTE J. M.; FALARDEAU J.; SUN M.; KANAZIRSKA M.; BROWN E. M.; \nSLAUGENHAUPT S. A. &amp; VASSILEV P. M. Identification and characterization of \nthe single channel function of human mucolipin-1 implicated in mucolipidosis type \nIV, a disorder affecting the lysosomal pathway. FEBS Lett, 532(1-2): 183-187, \n2002. \n\n34. MCGAUGH J. L. Memory--a century of consolidation. Science, 287(5451): \n248-251, 2000. \n\n35. MINGHETTI L. Role of inflammation in neurodegenerative diseases. Curr Opin \nNeurol, 18(3): 315-321, 2005. \n\n36. MYEROWITZ R.; LAWSON D.; MIZUKAMI H.; MI Y.; TIFFT C. J. &amp; PROIA R. L. \nMolecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by \ngene expression profiling. Hum Mol Genet, 11(11): 1343-1350, 2002. \n\n37. MYEROWITZ R. &amp; NEUFELD E. F. Maturation of alpha-L-iduronidase in \ncultured human fibroblasts. J Biol Chem, 256(6): 3044-3048, 1981. \n\n38. NEUFELD E. F. &amp; MUENZER E. The Mucopolysaccharidosis, in: SCRIVER, C. \nR., SLY W. S., CHILDS B., BEAUDET A. L., VALLE D., KINZLER K. W. &amp; \nVOGELSTEIN B. The Metabolic and Molecular Bases of Inherited Disease. 8a ed., \nNew York, McGraw-Hill, Cap. 78, 3241-3452, 2001. \n\n39. NEUMANN H. Microglia: a cellular vehicle for CNS gene therapy. J Clin Invest, \n116(11): 2857-2860, 2006. \n\n40. OHMI K.; GREENBERG D. S.; RAJAVEL K. S.; RYAZANTSEV S.; LI H. H. &amp; \nNEUFELD E. F. Activated microglia in cortex of mouse models of \nmucopolysaccharidoses I and IIIB. Proc Natl Acad Sci U S A, 100(4): 1902-1907, \n2003. \n\n41. PEDCHENKO T. V. &amp; LEVINE S. M. IL-6 deficiency causes enhanced \npathology in Twitcher (globoid cell leukodystrophy) mice. Exp Neurol, 158(2): 459-\n468, 1999. \n\n42. PELLED D.; RIEBELING C.; VAN ECHTEN-DECKERT G.; SANDHOFF K. &amp; \nFUTERMAN A. H. Reduced rates of axonal and dendritic growth in embryonic \nhippocampal neurones cultured from a mouse model of Sandhoff disease. \nNeuropathol Appl Neurobiol, 29(4): 341-349, 2003. \n\n43. PRESTI D. &amp; SCOTT J. E. Hyaluronan-mediated protective effect against cell \ndamage caused by enzymatically produced hydroxyl (OH.) radicals is dependent \non hyaluronan molecular mass. Cell Biochem Funct, 12(4): 281-288, 1994. \n\n44. QUEVEDO J.; VIANNA M. R.; MARTINS M. R.; BARICHELLO T.; MEDINA J. \nH.; ROESLER R. &amp; IZQUIERDO I. Protein synthesis, PKA, and MAP kinase are \ndifferentially involved in short- and long-term memory in rats. Behav Brain Res, \n154(2): 339-343, 2004. \n\n\n\n47 \n\n \n\n45. RAMPON C.; TANG Y. P.; GOODHOUSE J.; SHIMIZU E.; KYIN M. &amp; TSIEN J. \nZ. Enrichment induces structural changes and recovery from nonspatial memory \ndeficits in CA1 NMDAR1-knockout mice. Nat Neurosci, 3(3): 238-244, 2000. \n\n46. ROESLER R.; SCHRODER N.; VIANNA M. R.; QUEVEDO J.; BROMBERG E.; \nKAPCZINSKI F. &amp; FERREIRA M. B. Differential involvement of hippocampal and \namygdalar NMDA receptors in contextual and aversive aspects of inhibitory \navoidance memory in rats. Brain Res, 975(1-2): 207-213, 2003. \n\n47. RUSSELL C.; HENDSON G.; JEVON G.; MATLOCK T.; YU J.; AKLUJKAR M.; \nNG K. Y. &amp; CLARKE L. A. Murine MPS I: insights into the pathogenesis of Hurler \nsyndrome. Clin Genet, 53(5): 349-361, 1998. \n\n48. SERTIE A. L.; SOSSI V.; CAMARGO A. A.; ZATZ M.; BRAHE C. &amp; PASSOS-\nBUENO M. R. Collagen XVIII, containing an endogenous inhibitor of angiogenesis \nand tumor growth, plays a critical role in the maintenance of retinal structure and in \nneural tube closure (Knobloch syndrome). Hum Mol Genet, 9(13): 2051-2058, \n2000. \n\n49. TANG Y. P.; SHIMIZU E.; DUBE G. R.; RAMPON C.; KERCHNER G. A.; ZHUO \nM.; LIU G. &amp; TSIEN J. Z. Genetic enhancement of learning and memory in mice. \nNature, 401(6748): 63-69, 1999. \n\n50. VAN HORSSEN J.; WESSELING P.; VAN DEN HEUVEL L. P.; DE WAAL R. M. \n&amp; VERBEEK M. M. Heparan sulphate proteoglycans in Alzheimer's disease and \namyloid-related disorders. Lancet Neurol, 2(8): 482-492, 2003. \n\n51. VILLANI G. R.; GARGIULO N.; FARAONIO R.; CASTALDO S.; GONZALEZ Y. \nR. E. &amp; DI NATALE P. Cytokines, neurotrophins, and oxidative stress in brain \ndisease from mucopolysaccharidosis IIIB. J Neurosci Res, 85(3): 612-622, 2007. \n\n52. WADA R.; TIFFT C. J. &amp; PROIA R. L. Microglial activation precedes acute \nneurodegeneration in Sandhoff disease and is suppressed by bone marrow \ntransplantation. Proc Natl Acad Sci U S A, 97(20): 10954-10959, 2000. \n\n53. WALKLEY S. U. Secondary accumulation of gangliosides in lysosomal storage \ndisorders. Semin Cell Dev Biol, 15(4): 433-444, 2004. \n\n54. WALKLEY S. U.; BAKER H. J.; RATTAZZI M. C.; HASKINS M. E. &amp; WU J. Y. \nNeuroaxonal dystrophy in neuronal storage disorders: evidence for major \nGABAergic neuron involvement. J Neurol Sci, 104(1): 1-8, 1991. \n\n55. WALKLEY S. U.; HASKINS M. E. &amp; SHULL R. M. Alterations in neuron \nmorphology in mucopolysaccharidosis type I. A Golgi study. Acta Neuropathol, \n75(6): 611-620, 1988. \n\n56. WALLACE B. G. Agrin-induced specializations contain cytoplasmic, \nmembrane, and extracellular matrix-associated components of the postsynaptic \napparatus. J Neurosci, 9(4): 1294-1302, 1989. \n\n\n\n48 \n\n \n\n57. WRAITH J. E. The clinical presentation of lysosomal storage disorders. Acta \nNeurol Taiwan, 13(3): 101-106, 2004. \n\n \n\n \n\n\n\n49 \n\n \n\nCURRICULUM VITAE RESUMIDO \n\n \n\nREOLON G.K \n\n \n\n \n\n1. DADOS PESSOAIS \n\n \n\nNome: Gustavo Kellermann Reolon \n\nLocal e data de nascimento: Porto Alegre, RS, Brasil \u2013 14/12/1982 \n\nEndere\u00e7o profissional: Avenida Sarmento Leite, 500. 90041-970, Porto Alegre \n\nTelefone profissional: (51)33163892   E-mail: gkreolon@yahoo.com.br \n\n \n\n2. FORMA\u00c7\u00c3O \n\n \n\nMestrando em Biologia Celular e Molecular, no Programa de P\u00f3s Gradua\u00e7\u00e3o em \n\nBiologia Celular e Molecular, Universidade Federal do Rio Grande do Sul. Em \n\nandamento. \n\n \n\n2000-2004 Bacharel em Ci\u00eancias Biol\u00f3gicas, Universidade Federal do Rio Grande \n\ndo Sul. \n\n \n\n\n\n50 \n\n \n\n3. Est\u00e1gios: \n\n \n\nEst\u00e1gio: Est\u00e1gio de inicia\u00e7\u00e3o cient\u00edfica \n\nPer\u00edodo: mar\u00e7o de 2004 a dezembro de 2005 \n\nInstitui\u00e7\u00e3o: Universidade Federal do Rio Grande do Sul \n\nOrientador: Rafael Roesler \n\nBolsa: Propesq \n\n \n\nEst\u00e1gio: Est\u00e1gio de inicia\u00e7\u00e3o cient\u00edfica \n\nPer\u00edodo: novembro de 2003 a fevereiro de 2004 \n\nInstitui\u00e7\u00e3o: Universidade Federal do Rio Grande do Sul \n\nOrientador: Rafael Roesler \n\nBolsa: Est\u00e1gio volunt\u00e1rio \n\n \n\nEst\u00e1gio: Est\u00e1gio de inicia\u00e7\u00e3o cient\u00edfica \n\nPer\u00edodo: mar\u00e7o de 2001 a outubro de 2003 \n\nInstitui\u00e7\u00e3o: Universidade Federal do Rio Grande do Sul \n\nOrientador: Giancarlo Pasquali \n\nBolsa: FAPERGS \n\n \n\n\n\n51 \n\n \n\nEst\u00e1gio: Est\u00e1gio de inicia\u00e7\u00e3o cient\u00edfica \n\nPer\u00edodo: outubro de 2000 a fevereiro de 2001 \n\nInstitui\u00e7\u00e3o: Universidade Federal do Rio Grande do Sul \n\nOrientador: Giancarlo Pasquali \n\nBolsa: Est\u00e1gio volunt\u00e1rio \n\n \n\n4. ARTIGOS COMPLETOS PUBLICADOS \n\n \n\n1. MACHADO, M. S.; ROSA, R. M.; DANTAS, A. S.; REOLON, G. K.; APPELT H. \nR.; BRAGA, A. L.;  HENRIQUES, J. A. &amp; ROESLER, R. An organic selenium \ncompound attenuates apomorphine-induced stereotypy in mice. Neurosci Lett, \n27;410(3):198-202, 2006. \n\n2. REIRIZ, A. B.; REOLON, G. K.; PREISSLER T.; ROSADO, J. O.; HENRIQUES, \nJ. A.; ROESLER, R. &amp; SCHWARTSMANN G. Cancer chemotherapy and cognitive \nfunction in rodent models: memory impairment induced by cyclophosphamide in \nmice. Clin Cancer Res, 15;12(16):5000, 2006. \n\n3. REOLON, G. K.; BRAGA L. M.; LUFT, T.; HENRIQUES, J. A.; NARDI, N. B. &amp; \nROESLER, R. Long-term memory for aversive training is impaired in Idua(-/-) \nmice, a genetic model of mucopolysaccharidosis type I. Brain Res, 1076(1):225-\n230, 2006. \n\n4. ROESLER, R.; REOLON, G. K.; LUFT, T.; MARTINS, M. R.; SCHRODER, N.; \nVIANNA, M. R. &amp; QUEVEDO J. NMDA receptors mediate consolidation of \ncontextual memory in the hippocampus after context preexposure. Neurochem \nRes, 30(11):1407-1411, 2005. \n\n \n\n\n\tDisserta\u00e7\u00e3o parte 2- Gustavo Reolon.pdf\n\tLong-term memory for aversive training is impaired in Idua?/? mice, a genetic model of mucopoly.....\n\tIntroduction\n\tResults\n\tOpen field behavior\n\tNovel object recognition\n\tInhibitory avoidance\n\tFootshock reactivity\n\n\tDiscussion\n\tExperimental procedures\n\tAnimals\n\tBehavioral testing\n\tOpen field behavior\n\tNovel object recognition\n\tInhibitory avoidance\n\tFootshock reactivity\n\n\tStatistics\n\n\tAcknowledgments\n\tReferences\n\n\n\tDisserta\u00e7\u00e3o parte 4- Gustavo Reolon.pdf\n\tAlterations in Oxidative Markers in the Cerebellum ?and Peripheral Organs in MPS I Mice\n\tAbstract\n\tIntroduction\n\tMethods\n\tAnimals\n\tSuperoxide Dismutase Activity\n\tCatalase Activity\n\tGlutathione Peroxidase Activity\n\tProtein Damage\n\tLipid Peroxidation\n\tStatistical Analysis\n\n\tResults\n\tDiscussion\n\tAcknowledgments\n\tReferences"}]}}}